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1. Introduction 
1.1 Chronic Kidney Disease 
 According to recent statistics by the Center for Disease Control and Prevention 
(CDC), chronic kidney disease (CKD) has been placed 9th on the list of leading causes 
of death in the USA in 2007 [1]. CKD is defined as an irreversible and progressive 
decline of kidney function leading to kidney failure, known as end stage renal disease 
(ESRD). It has been estimated that 14-15% of the adult population in the USA is 
affected by CKD and its prevalence has been estimated to increase by 50 % over the 
next two decades [2]. Hypertension, diabetes, infections, glomerulonephritis, 
glomerulosclerosis and renal disease associated with genetic disorders are risk factors 
for developing CKD. In 2002, the National Kidney Foundation Kidney Disease Quality 
Outcome Initiative (NKF-K/DOQI) published the first guidelines to define and classify 
CKD. First in 2005 and later in 2013, the Kidney Disease Improving Global Outcomes 
(KDIGO) provided, in accordance with the document from K/DOQI, a revised 
definition of CKD[3-6]. In the latest document, CKD is defined by structural or 
functional abnormality of the kidney (albuminuria > 3 mg/mmol; glomerular filtration 
rate (GFR) < 60 ml/min/1.73 m2 present for 3 months, with implications for health. This 
document provides an updated and revised guide for the management and classification 
of CKD based on five GFR and three albuminuria categories. 
 
 
 
Table 1. Criteria for CKD (taken and adapted from New KDIGO CKD 2013 [6]) 
 
Markers of Kidney damage (one or more) Albuminuria (AER >30 mg/24 h; ACR >30 mg/g 
[>3 mg/mmol]) 
Urine sediment abnormalities 
Electrolyte and other abnormalities due to tubular 
disorders 
Abnormalities detected by histology 
Structural abnormalities detected by imaging 
History of kidney transplantation 
Decreased glomerular filtration rate (GFR) GFR < 60 ml/min/1.73 m2 (GFR categories G3a–
G5) 
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Table 2. GFR categories in CKD (taken and adapted from New KDIGO CKD 2013 [6]) 
*Relative to young adult level 
 
Table 3. Albuminuria categories in CKD (taken and adapted from New KDIGO CKD 2013 [6]) 
 
*Relative to young adult level. 
**Including nephrotic syndrome (albumin excretion usually >2200 mg/24 h [ACR >2220 mg/g; >220 
mg/mmol]). 
 
 
1.1.1 Pathogenesis of glomerulosclerosis 
 Sclerosis of the glomerulus occurs as a response to injury. The parenchyma is 
then replaced by scarring tissue, leading to progressive and irreversible loss of function. 
The glomerular structure consists of an endocapillary compartment containing 
mesangial cells and capillaries, and an extracapillary compartment containing podocytes 
and the parietal epithelial cells (PECs) lying on the Bowman´s capsule [7, 8]. The 
harmony and the functionality of this architecture are maintained by podocytes. 
Podocytes, also known as glomerular visceral epithelial cells, are terminally 
differentiated epithelial cells that are specialized to their architecture, and are 
responsible for the maintenance of the glomerular filtration barrier (GFB).  A recent 
study was able to show that all forms of glomerulosclerosis start with either a lesion or a 
dysfunction of podocytes [9]. This is a common feature of many clinical pathologic 
GFR category GFR (ml/min/1.73m2) Terms 
G1 ≥ 90 Normal or high 
G2 60-89 Mildly decreased* 
G3a 45-59 Mildly to moderately decreased 
G3b 30-44 Moderately to severely decreased 
G4 15-29 Severely decreased 
G5 <15 Kidney failure 
Category AER(mg/24h) ACR(mg/g) Terms 
A1 <30 <30 Normal to mildly increased 
A2 3-300 3-300 Mildly increased* 
A3 ≥ 300 ≥ 300 Severely increased** 
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syndromes including hereditary glomerular disease and kidney disease with late onset 
like diabetic disease [10, 11], focal segmental glomerulosclerosis (FSGS), membranous 
glomerulopathy or amyloid nephropathy [12, 13]. As a consequence of their high degree 
of differentiation and complexity, podocytes have a limited capacity for cell cycle re-
entry and thus for replacing podocyte loss [14]. Remaining podocytes may compensate 
this loss by one of the following mechanism: 
• Activating stem cell recruitment [15-17]  
• Cell hypertrophy taking over the increased workload [18] 
 Independent of the mechanism involved, podocyte hypertrophy or replacement 
occurs slowly. Insufficient repair can lead to podocytopenia and subsequently threaten 
glomerular integrity [19]. The classical concept of development and progression of 
glomerulosclerosis has been accurately described in several animal models [20, 21] 
 The major culprit in the progression of glomerulosclerosis is the podocyte. Upon 
insult, podocyte loss and the failure of neighboring podocytes to cover the defect will 
result in a formation of naked glomerular basement membrane (GBM) area. Loss of 
separation between the capillary tuft and the Bowman´s capsule allow PECs of the 
Bowman´s capsule to access the GBM leading to a parietal “beach head” on the tuft. 
PECs attach to the capillary tuft giving rise to a gap and displacing podocytes to the 
GBM, establishing a synechia, which represents the first step in the development of 
segmental glomerulosclerosis [22]. This adhesion might develop either into a 
proteinaceous crescent based on the misdirected filtration towards the cortical 
interstitium, characteristic of the degenerative kidney disease, or into a cellular mixed 
crescent generally found in inflammatory kidney disease [9]. In the early stage of 
crescent formation, the cellular compositions of crescents appear to change over time 
with a predominance of proliferating PECs [23-25].  
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Figure 1. Schematic to show the progression of segmental to global glomerulosclerosis. (a) 
Normal glomerulus with vascular and urinary poles. Smooth muscle cells, extra glomerular 
mesangial cells, and mesangial cells are hatched; podocytes are shown in blue-green, parietal 
epithelial cells in red. The GBM is shown in black, the parietal basement membrane in yellow, 
tubular epithelia are shown in white (b) .A denuded capillary is attached to Bowman’s capsule. 
Parietal cells attach to the naked GBM. (c) The adhesion has spread to neighboring capillaries 
resulting in either the collapse or in hyalinosis (shown in a dark grey pattern). The parietal 
epithelium may either appose the degenerated podocytes (arrowhead) or attach directly to the 
GBM at the flanks of the adhesion. Fluid leakage from perfused capillaries inside the adhesion 
has created a paraglomerular space (shown in yellow) that contains the sclerotic tuft remnants 
(that is, collapsed or hyalinized GBM formations). Towards the cortical interstitium this 
paraglomerular space has become separated by a layer of sheet-like fibroblast processes (shown 
in green). (d) The sclerotic process jumps, via the vascular pole, to a neighbouring lobule. Even 
in late stages of injury perfused capillaries are regularly found within the sclerotic regions. In 
later stages, In the sclerotic area invaded by cortical fibroblats, fibrosis will appear. (Taken from 
Kriz et al., 1998 [21]) 
 
 
  
 11 
 
 In the latter stage, the capillary tuft inside the adhesion either collapses or is 
occluded by hyalinosis, and the podocyte located next to the synechia will degenerate 
by a variety of mechanisms. Abnormal fluid leakage from perfused capillaries onto/into 
the outer surface of the glomerulus creates a para-glomerular space. Here, an infiltration 
of macrophages, lymphocytes and myofibroblasts can be observed, accompanied by a 
sustained deregulation of PEC proliferation [24, 26]. Later, fibroblast will establish a 
dense sheet-like fibrous organization to enclose the focus of misdirected filtration, 
forming a fibrous crescent. PECs play an active role in the progression from cellular to 
fibrous crescents, producing monocyte chemo-attractants (MIP-1a and MIP-1b) and IL-
8, a chemokine involved in the transmigration of neutrophils into the peri-glomerular 
and intra-glomerular space [27-29].  Furthermore, PECs contribute to the scaring of 
crescents by producing extracellular matrix molecules and pro-fibrotic growth factors 
[30-33]. Crescent formation may stop after an entire lobule has been engulfed 
presenting a segmental synechia. Yet, this process compromises the other lobules 
leading to global sclerosis [22] (Figure 1). 
 Podocyte loss and aberrant proliferation of PECs are crucial events for initiating 
the scar formation and glomerular remodeling process. There are several studies with 
transgenic animal models that have shown a correlation between the severity and 
progression of sclerotic lesions and the degree of podocyte loss [19, 34, 35] (Figure 2). 
When mild podocyte loss is accruing (20% or less) the effects on the glomerular 
architecture are subtle, that is to say little capsular adhesion formation with transient 
mild proteinuria and no measurable change in renal function [36]. It can be 
hypothesized that the remaining podocytes have the capacity to rapidly cover the 
denudated GBM, due in part to the recruitment of progenitor stem cells from the 
Bowman’s capsule [37, 38]. Podocyte loss of 40% is associated with synechiae 
formation, FSGS and low-level proteinuria in absence of change in renal function [36]. 
Probably, the remaining podocytes cannot compensate for the GBM area exposed 
within the critical time and the scar formation can be seen as result of an inefficacious 
repair mechanism [36, 38]. When podocyte depletion exceeds 40% an increased 
proportion of glomeruli with adhesion to the Bowman’s capsule, a high level of 
proteinuria and decreased renal function is observed. Similarly, this has been described 
in human biopsy material [39, 40]. 
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Figure 2. Photomicrographs of glomeruli from rats with increasing podocyte depletion at 
28 d. Sections are stained for podocytes by immunoperoxidase anti-GLEPP1 (brown) and 
counterstained by PAS (pink) and hematoxylin (blue). In the box at the top left of each 
photomicrograph, the average proportion of podocytes depleted for that animal as counted by 
WT-1 nuclear staining is shown. The normal small amount of pink-stained mesangial space is 
shown (A). As podocyte number is depleted by up to 23%, the amount of PAS-positive (pink) 
space increases (B and C). At 28% podocyte depletion, adhesions between the glomerular tuft 
and Bowman’s capsule can be seen (E). With further podocyte depletion, increasingly larger 
segments of glomeruli are sclerotic and devoid of podocytes (F through H). With _90% 
podocytes depleted, some glomeruli contain no detectable podocytes and a collapsing sclerotic 
appearance (I). We conclude that there was a proportionate change in histologic features in 
relation to theproportion of podocytes lost in the model. Bars _ 50 _m. (Taken from Wharram et 
al., 2007 [36]) 
 
 
1.1.2 Focal segmental glomerulosclerosis 
 Focal segmental glomerulosclerosis is not a single disease but rather a group of 
clinical-pathologic syndromes sharing a common glomerular lesion and mediated by 
different types of insult within podocytes [41]. FSGS is characterized by the presence of 
focal and segmental lesions with mesangial sclerosis, obliteration of glomerular 
capillaries with hyalinosis and foam cells, adhesion with the glomerular tuft and 
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Bowman´s capsule, and podocyte hypertrophy [27]. Even though the pathogenesis of 
FSGS has been the subject of many studies, 80% of FSGS cases are classified as 
idiopathic (primary), where the cause is unknown, or it is believed that they are related 
to circulating permeability factors. Recently elevated serum levels of soluble urokinase 
receptor have been reported in up to 2/3 of patients with primary FSGS. Both, the 
mechanisms involving this receptor and course of podocyte foot process effacement 
have been demonstrated [42]. Genetic mutation affecting podocytes proteins have been 
identified in up to two thirds of the familial and sporadic types of FSGS already present 
within the first year of life [43]. Most of these mutations, correlate with the nephrotic 
syndrome and have been found in genes coding for podocyte proteins located in the slit 
diaphragm (nephrin, podocin and CD2-associated protein) [44-46], cell membrane (β4 
integrin, CD151, TRPC6 and lamininbeta2) [47-49], cytosol (PLCE) [50], cytoskeleton 
(INF2, nonmuscle myosin IIA,ACTN4 and MYo1E) [51-54], nucleus (WT-1) [55, 56] 
and mitochondria (COQ6) [57]. Other forms of secondary FSGS have been attributed to 
viral infections (human immunodeficiency virus type 1, parvovirus B19, simian virus 40 
and Epstein-Barr virus) [58-61] or to drug abuse (Heroin; IFN-α/β and IFN-γ: lithium; 
parmidronate; sirolimus; calcineurin-inibitor nephrotoxicity; anabolic steroids)[62-64]. 
Sclerotic lesions observed in FSGS differ anatomically in their location and quality with 
respect to glomerular hypercellularity and capillary collapse [41]. The light microscopic 
morphology and the location of sclerotic lesions are used to define the histological 
variants of FSGS: cellular variant (hypercellularity of the capillary space), tip variant 
(lesion involving the tubular pole), perihilar variant (involving sclerosis of the vascular 
pole), collapsing variant and   not-otherwise-specified (NOS) variant (Figure 3).  
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Figure 3. Histological variants of Focal Segmental Glomerulosclerosis. Cytomegalovirus. 
(CMV), Epstein-Barr virus type 1 (EBV) and Simian virus 40 (SV40). (Taken from D'Agati et 
al., 2011 [41]) 
 
 
1.1.3 Adriamycin-induced focal segmental glomerulosclerosis  
 Adriamycin nephropathy is a highly reproducible and robust model of chronic 
proteinuric renal disease, resulting from selective podocyte injury [65]. In rodents, a 
single injection of adriamycin, induces kidney damage that mirrors human focal 
segmental glomerulosclerosis. Adriamycin (doxorubicin) is an anthracycline antibiotic 
with pleiotropic cytotoxic effects, used for treatment of a wide spectrum of human 
cancers. It is a DNA intercalating agent, which inhibits the enzyme topoisomerase II 
and thereby generates free radicals, which induce DNA damage and subsequent cell 
death [66]. Detailed pharmacokinetic studies showed that adriamycin is not significantly 
metabolized, however it is rapidly cleared from the plasma, deposited in tissue (mainly 
in the kidney) and slowly excreted into urine and bile. There is a well-known variability 
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in the susceptibility across strains due to a single gene defect with recessive inheritance 
located on the chromosome 16. The susceptibility alleles at this locus are associated 
with blunted expression of protein arginine methyltransferase7 (Prmt7), a protein 
implicated in cellular sensitivity to chemotherapeutic agents [67, 68]. BALB/c and 
derived inbred strains (e.g severe combined immunodeficient mice, SCID) show high 
susceptibility to adriamycin injection compared to C57BL/c mice who are highly 
resistant. 
 1-2 weeks after adriamycin administration, altered renal function and induced 
thinning of the glomerular endothelium together with specific damage at the filtration 
barrier, are observed. Increased free radical production [69] in the kidney and changes 
associated with key proteins of the slit diaphragm (nephrin, podocin and NEPH1) are 
the main mechanisms of adriamycin functionality [70]. Histological assessments of 
kidneys from animals injected with adriamycin show severe tubule interstitial 
inflammation with marked infiltration by immune cells (T and B lymphocytes and 
macrophages)[65]. However, studies in SCID mice have demonstrated that the 
structural and functional injury induced by adriamycin does not necessary require 
immune cell activation [71].  
 
 
1.1.4 Podocytes  
  The renal corpuscle is a tuft of capillary loops supported by mesangial cells and 
surrounded by a basement membrane and podocytes [72, 73]. During nephrogenesis, 
four different stages of glomerular development are defined: vesicle stage, S-shaped 
body stage, developing capillary loop stage, and maturing stages (Figure 4). During the 
vesicle stage, precursor cells of the glomerular and tubular epithelium are joined by 
occluding junctions at their apices [74]. During the S-shape body stage epithelial 
precursor cells with apically located tight junction form the immature podocyte 
precursor population. At this stage, podocyte specific protein expression commences 
[73]. This includes the expression of podocalyxin and the tight junction protein zonula 
occludens-1 (ZO-1) and the transcription factors Williams tumor protein-1 (WT-1) and 
Pod-1 [75-78]. When podocyte precursor like cells enter the capillary loop stage, they 
lose their mitotic activity and branch into specialized cell architecture which involves a 
neuron-like complex differentiation process including the formation of foot processes 
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and slit membrane [73] [79]. The phonotypical conversion occurring during the S-shape 
body stage is accompanied by the expression of synaptodin [80] and by the 
reappearance of vimentin [81]. Mature podocytes are polarized cells with three well-
defined and separated domains: a cell body, primary process and foot process. The foot 
processes have three separate membrane platforms: the apical membrane domain, the 
slit diaphragm and the basal membrane domain. Each domain has a unique function for 
facing different environments that are both physically and functionally linked to the 
actin cytoskeleton of the foot processes. The variety of proteins located on the podocyte 
membrane is indicative for this specialization [82]. There is a multitude of signaling 
events, including integrin activation and calcium influx, coming from these foot 
processes which modulate active reorganization of actin filaments and allow podocytes 
to change their morphology and regulate the permeability of the filtration barrier [83]. 
Interference with any of the components of the actin cytoskeleton results in foot process 
effacement and loss of the normal interdigitating patterns, leading to proteinuria. 
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Figure 4. Development of the nephron. During the induction of the metanephric mesenchyme, 
cells condense around the tips of the branching ureteric bud, and convert to an epithelial cell 
type (MET, mesenchymal-to-epithelial transition). These early epithelial cells form a spherical 
cyst called the renal vesicle (B), the renal vesicle aggregates to the comma-shaped (C), and then 
the S-shaped bodies (D). At this stage, the proximal end of the S-shaped body becomes invaded 
by blood vessel, differentiates into podocytes and parietal epithelial cells, and then generates the 
glomerular tuft (E, F). Simultaneously, the middle and the distal segments of the S-shaped body 
that had remained in contact with the ureteric bud epithelium fuse to form a single, continuous 
epithelial tube and begin to express proteins that are characteristic of tubular epithelia (taken 
from Romagnani, 2009 [84]) 
 
 
1.1.5 Podocytes and the glomerular filtration barrier 
 The glomerular filtration barrier is a highly specialized blood filtration interface 
that displays permeability to small- and midsized solutes in plasma, but restricts the 
flow of larger plasma proteins into the urinary space (Figure 5).  The GFB is a three-
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layered structure consisting of endothelial cells, GBM and podocytes [85, 86].  
Podocytes, located outside of the glomerular capillary loop, play a crucial role in the 
formation and maintenance of the glomerular filtration barrier. They have a complex 
cellular organization consisting of a large cell body leaning out of the urinary space and 
long cellular extensions (foot processes) that interdigitate with those of neighboring 
podocytes to cover the outer part of the GBM [85]. Podocyte foot processes are 
anchored to the GBM through α3βintegrins and β-dystroglycans [87]. These 
characteristics, interdigitating patterns between foot processes of neighboring podocytes 
are bridged by a 40nm wide zipper-like slit diaphragm [88]. Podocyte foot processes 
and the interposed slit diaphragm cover the outer part of the GBM and play a major role 
in establishing the selective permeability of the glomerular filtration barrier [73]. The 
GFB is highly permeable to water and small solutes, but the small pore size (5-15nm) of 
the slit diaphragm limits the passage of larger proteins, for example albumin [89]. 
 
 
 
Figure 5 Schematic representations of glomerulus and glomerular filtration barrier. The 
GFB comprised of fenestrated glomerular endothelial cells, glomerular basement membrane and 
podocytes. The parietal epithelial cells are present along the Bowman´s basement membrane. 
(The image was adapted from Leeuwis J.W. et. al. [90]) 
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1.1.6 Podocytes and the cell cycle control 
 During glomerulogenesis podocyte precursors proliferate during the S-shape 
body stage, but this capacity, within the transition to the capillary stage and the fully 
differentiated phenotypic switch, is lost. Studies showed that during glomerulogenesis a 
transient expression of p21 occurs, and the transition from a proliferating immature 
podocyte to a mature quiescent phenotype coincides with the de novo expression of the 
CKD inhibitors p27 and p57 [14, 91].  These CKD inhibitors are constitutively 
expressed in the mature podocyte and they contribute to maintaining a non-proliferating 
podocyte phenotype [14, 91, 92]. Certain glomerular diseases, like the cellular variant 
of FSGS, idiopathic CG, and HIVAN have been apparently reported to be associated 
with abnormal podocyte proliferation. In these diseases a uniformly decreased 
expression of p27 and p57, accompanied by the de novo expression of p21 in podocytes 
has been reported [93]. This form of non-reparative proliferation mechanism by 
podocytes, leading to a disruption of the glomerular architecture, is likely controlled by 
an aberrant reduction of CDK inhibitor expression, rather than a normal biological 
function of podocytes [92]. The tight regulation of cell cycle quiescence in podocytes, is 
needed to guaranty their highly specialized structure and function [94]. 
 
 
1.1.7 Podocytes response to injury: apoptosis or mitotic catastrophe? 
Despite strong evidence that podocyte damage and loss is a prerequisite for 
glomerular sclerosis, the mechanisms through which podocytes respond to injury are 
still controversial. Based on the literature, it can be hypothesized that, independent of 
the type of insult, the podocyte responds to injury first by retracting their foot processes 
and later by detaching from the GBM and/or die [95]. How does podocyte death take 
place? Although evidence for terminal deoxynucleotidyl transferase mediated dUTP 
Nick End Labeling (TUNEL)-positive apoptotic podocytes has been reported, these 
accounts pertain only to particular environmental conditions and to a very low apoptotic 
rate [96]. Apoptosis of glomerular podocytes has been reported more often in-vitro than 
in-vivo [97]. Only a few studies, using animal models of progressive glomerular 
sclerosis, like diabetic mouse models, TGF-β transgenic mouse models and alport 
mouse models, have demonstrated podocyte apoptosis, detected by TUNEL staining 
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[98-100]. For example in alport model, characterized by an increased intrarenal 
expression of TNF-α, it has been observed that treatment with entanercept (TNF-α 
inhibitor) substantially ameliorates renal function and reduces apoptosis in podocytes 
(quantified by TUNEL staining). This highlighting the role of TNF-α in mediating 
apoptosis as a putative pathway of podocyte death [100]. So far, however, there is little 
scientific evidence supporting apoptosis as a general pathway of podocyte death in-
vivo, suggesting an alternative way for podocyte death. Podocytes are terminally 
differentiated post-mitotic cells, regulating tightly their quiescent cell cycle. This is a 
prerequisite to guaranty their highly specialized structure and function. The 
development of an altered proliferative podocyte phenotype, bypassing the cell cycle 
check points, can be observed in certain glomerular diseases. This might represent a 
general mechanism of podocyte response to injury, ultimately leading to death [101-
104]. A recent study reported that forced entry in mitosis is a trigger for mitotic 
catastrophe in podocytes, because these cells, even if they can initiate DNA synthesis 
and chromosome segregation, cannot complete cytokinesis due to poor expression of 
Aurora Kinase B, which is essential for this process [95, 105, 106] (Figure 6). 
Abnormal mitotic podocytes expressing histone H3 were observed in adriamycin-
induced FSGS models and podocyte death through catastrophic mitosis was prevented 
by treatment with Notch inhibitors. This Notch activation mediated down regulation of 
cell cycle inhibitors that force podocytes to progress toward mitosis [105]. Forced cell 
cycle re-entry of podocytes has been described as a consequence of conditional over 
expression of telomerase reverse transcriptase enzyme. Subsequent regulation of Wnt 
signaling resulted in collapsing glomerulopathy [107].  
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Figure 6. Pathological activation of podocyte cell cycle induces re-entry into G1 and S-
phases and initiation of DNA replication. Podocytes complete the DNA synthesis but cannot 
proceed through the M phase owing to the activation of mitotic catastrophe. Cells arrested in 
mitosis can have different fates: a) increase their size thus becoming hypertrophic; b) when 
division cannot be complete and cytokinesis fails, cells with gross nuclear alterations 
(multinucleation) are generated which quickly undergo “mitotic death” program; c) cells can 
exit mitosis containing a variable number of nuclei or micronuclei; these cells are viable 
because lethal pathway is not executed until cells reach interphase of the next cell cycle, but are 
unstable and detach from the GBM; in this case, cell death can occur in a delayed fashion even 
after years; d) when the aberrant division is productive aneuploidy cells form; most of these are 
unviable, owing to chromosomal rearrangements that result in progressive detachment to 
eliminate genomically unstable cells. (Taken from Lasagni et.al 2013)[104] 
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1.1.8 Podocytes and parietal epithelial cells 
 Besides visceral epithelial cells and their major role in maintaining the 
glomerular filtration barrier, little attention has been given to the other glomerular 
epithelial cells: PECs of the Bowman’ s capsule. Sir William Bowman first described 
these cells in 1842, as “flattened, inconspicuous cells pressed against the Bowman’s 
capsule. PECs derive from the metanephric mesenchyme and their phenotype diverges 
from that of podocytes at the latter stages of kidney development [74, 108]. During the 
S- shaped body stage the Bowman’s space begins to form, limited outside by a narrow 
band of PECs, and inside by a crown of visceral epithelial cells, the future podocytes 
[84, 109, 110]. During nephrogenesis both glomerular epithelial progenitors express 
common transcription factors like Pax-2, WT-1 and the keratin-containing intermediate 
filament, cytokeratin. Together with the acquisition of a differentiated phenotype, 
podocyte lose Pax-2 expression, but continue to express WT-1 and begin to express 
vimentin instead of cytokeratin. [111, 112] By contrast, during maturation, PECs lose 
WT-1 expression, but continue to express Pax-2 and cytokeratin proteins [27]. In the 
past, the close resemblance between PECs and podocytes has restricted researchers to 
distinguish these two cell types only on the basis of anatomical criteria. Recently 
discovered specific markers and the advent of genetic tagging has improved the 
characterization of their distinct role in renal physiology and pathology [25, 110]. 
Mature PECs express cadherins, a variety of tight junction proteins (like claudins), 
occludins and the Pax-2 and Pax-8 [113]. PECs form a monolayer lining on the 
Bowman's basement membrane, which resembles squamous epithelial cells, with a 
small cell body size ranging in thickness from 0.1 to 0.3 µm, increasing to 2.0–3.5 µm 
at the nucleus [114]. In-vivo and in-vitro studies have reported that the PECs monolayer 
might function as a final permeability barrier to the urinary filtrate [115] Scanning 
electron microscopy studies showed that PECs possess microvilli and  primary cilia  
which are constantly exposed to flow from  the glomerular filtrate, giving to PECs a 
mecchano-sensing function through its cilia [114, 116]. In humans the PEC population 
has been isolated and characterized as a stem cell population, which shows the ability to 
produce new podocytes, both in-vivo and in-vitro, opening prospective of new 
regenerative therapies. [117].   
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1.1.9 Podocytes regeneration from glomerular progenitors 
 Unlike other organs, such as liver or skin, the kidney, particularly the 
glomerulus, has been classically considered as an organ with minimal cellular turnover 
and low capacity for regeneration. Mesangial and endothelial cells have been reported 
to have the capacity to proliferate and replace the loss of neighboring cells upon insult, 
but this does not apply to visceral epithelial cells. Podocytes are terminally 
differentiated cells and are unable to proliferate, which might explain how the loss of 
such specialized cells is a common cause of kidney failure [38]. Data from experimental 
models have demonstrated that a regression of glomerulosclerosis can occur by 
increasing the number of podocytes, yet the underlying mechanisms are still poorly 
understood. Since podocytes cannot undergo mitosis, new podocytes might derive from 
a regeneration process rather than from podocyte proliferation [38, 118, 119]. However, 
the presence and biological role of kidney stem cells has been in debate.[120-122]. 
Recently, it has been proved that adult human glomeruli contain resident stem cell 
populations and committed progenitor cells localized at the urinary pole of the 
Bowman’s capsule. This population is identified by the presence of CD24 and CD133 
[84, 123, 124] and exhibits self-renewal properties. Further, they have the potential to 
either differentiate into podocytes or into tubular cells, in-vitro and in-vivo [38, 125].  
Other studies using parietal epithelial tagging in mouse models confirm the findings 
reported on humans [120]. They were able to demonstrate that such cells proliferate and 
differentiate along the urinary space and move to the vascular stalk, generating neo-
podocytes. However, in glomerular disorders, characterized by acute or severe podocyte 
loss, the regenerative capacity of epithelial glomerular stem cells is inadequate because 
of an imbalance between the proliferative response and the degree of damage [16, 126]. 
Glomerular epithelial stem cells display different regenerative potentials throughout 
distinct stages of their life and are modulated by the surrounding environment [127, 
128]. In addition, crescentic glomerulonephritis or collapsing glomerulopathy show 
aberrant migration and excessive proliferative response by glomerular epithelial stem 
cells.  This reflects the inability to restore lost podocytes, contributing to crescent 
formation and glomerulosclerosis [25, 33, 37]. 
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1.2 Viral infection and Glomerulonephritis 
 Viral infections can cause a large spectrum of nephropathies. Several 
mechanisms are involved in the pathogenesis of virus-related nephropathy: 
• direct cytopathogenic effects due to the tropism of the virus in the kidney  
• induction of abnormal circulating immune complexes involving viral antigens or 
endogenous antigens modified by viral infection and host autoantibodies 
• expression of viral proteins in tissues, inducing cell death and release of 
proinflammatory cytokines and chemokines. 
Different viral infections can cause different nephropathies. In acute glomerulonephritis, 
direct viral infections of the glomerulus can induce proliferative changes, following the 
release of inflammatory cytokines [129]. Hepatitis A virus infections can cause an acute 
post infection glomerulonephritis with a pathology resembling IgA nephropathy [130]; 
Epstein-Barr virus and Parvovirus B19 (PVB19) infections have been associated with 
acute glomerulonephritis [131, 132].  
  PVB19 infections are also associated with chronic forms of glomerulonephritis, 
along with human immunodeficiency virus (HIV), Hepatitis B (HBV) and Hepatitis C 
(HCV) infections. Persistent virus infections provide continuous antigenic stimulation, 
resulting in antibody production and formation of immune complexes outside the 
kidney or in situ [133, 134]. A direct effect of viral proteins has been proved to increase 
inflammatory mediator production locally, resulting in glomerular sclerosis [129, 135]. 
Membranoproliferative glomerulonephritis (MPGN) is the most common HCV-related 
nephropathy, usually in the context of cryoglobulinemia [136, 137] whereas chronic 
HBV infection can cause IgA nephropathy. [138, 139]. Besides the classical HIV-
associated nephropathy (HIVAN), HIV infection can give rise to a wide spectrum of 
glomerular lesion. In the course of HIV infection, has been reported a diffuse 
proliferative-mesangiocapillary glomerulonephritis, with predominantly mesangial 
immune-complex deposition, resembling lupus nephropathy [140].  Additionally, renal 
biopsy data from HIV patients with renal disease show that podocytes are infected with 
the virus [141], even in absence of the classical HIV receptors CD4, CXCR4 and CCR5, 
indicating that the viral infection is the cause of podocyte dysfunction [142]. PVB19 is 
also associated with chronic glomerulonephritis, particularly with collapsing 
glomerulonephritis. Here, viral DNA has been detected in glomerular podocytes and 
PECs [58].  
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1.2.1 Virus-induced focal segmental glomerulosclerosis: HIV-associated nephropathy 
 HIV-associated nephropathy is the most common cause of chronic kidney failure 
and end stage renal disease seen in patients with acquired immunodeficiency syndrome 
(AIDS)[143]. The collapsing variant of focal segmental glomerulosclerosis, together 
with tubular interstitial damage and focal prominent interstitial inflammatory cellular 
infiltrates are the most characteristic pathological changes in HIVAN. In most cases, all 
the glomeruli are affected by extensive collapse of the glomerular capillary lumen and a 
prominent hyperplasia of podocytes [61, 144]. 
 Nearly 90% of the patients affected with HIVAN are African Americans; the 
prevalence of HIVAN among the African Americans has been correlated with strong 
genetic predisposition linked to African descent. Genetic studies have identified two 
genetic loci associated with susceptibility to HIVAN; polymorphisms in the MYH9 
gene, expressed in visceral epithelial cells, which encodes nonmuscle myosin heavy 
chain IIA and in the neighboring gene APOL1, which encodes apolipoprotein L1 [145-
147]. However, these studies did not elucidate any biological mechanism for the 
increased risk of FSGS associated with these genetic variants. 
 A direct role for HIV infections in the pathogenesis of HIVAN has been 
demonstrated in animal models (Tg26 HIV-transgenic mouse) and subsequently in 
human kidney tissue [141, 148]. Animal models and in-vitro studies have elucidated the 
importance of the viral gene nef in the development of glomerular lesions correlated 
with podocyte changes [149, 150]. Further studies suggest that renal epithelial cells, 
which do not express CD4 or the traditional co receptors for HIV, might be able to 
support low level viral replication, although there is no evidence of productive infection 
in these in-vitro system [151, 152]. 
 
 
1.2.2 Interferons type I-induced focal segmental glomerulosclerosis 
 Interferons (IFNs) are potent inflammatory cytokines with distinct functions and 
targets. The IFNs family is dived into two main groups, type I and type II IFNs. IFN-
α and IFN-β, belongs to type I IFNs and virally infected cells usually produce them. 
The type I IFNs response is crucial for the control of viral infections. They induce 
cellular changes in neighboring cells that prevent viral replication and protein synthesis 
and they activate the adaptive immune system [63, 153]. Endogenous production is 
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strictly regulated by the innate immunity pattern recognition receptors, and aberrant 
IFNs type I production is associated with autoimmune disease like Systemic lupus 
erythematosus (SLE)[154]. Exogenous administration of IFN-α is used as a therapeutic 
agent for the treatment of HBV and HCV infections, follicular lymphoma and AIDS 
related Kaposi sarcoma. IFN-β , is indicated and approved for the treatment of multiple 
sclerosis (MS). Type I IFNs treatment is associated with renal adverse effects, like 
minimal change disease and FSGS [155-160]. However, reports on FSGS and 
collapsing FSGS have increased during the past years.  
 IFNs are known to play a central role in innate and adaptive immune responses 
through the activation of innate and adaptive immune cells [161]. Activation and 
recruitment of lymphocytes and macrophages are key processes in inflammatory kidney 
disease associated with the FSGS scenario, like in lupus nephritis [154, 162]. In 
addition, it has been shown that podocytes have the receptor for IFN-α and IFN-β, 
suggesting a primary cytotoxic effect of IFNs on podocytes [41]. 
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Table 4. Published reports of FSGS after treatment with IFN type I (taken and adapted 
from Markowitz et.al 2010 [62]). 
 
IFN type Renal 
presentation 
Renal biopsy findings 
α Nephrotic Syndrome, 
Acute renal failure 
Focal segmental glomerulosclerosis 
α −2a Nephrotic Syndrome, 
Acute renal failure 
Focal segmental glomerulosclerosis 
α−2b Nephrotic Syndrome, 
Acute renal failure 
Focal segmental glomerulosclerosis 
α Nephrotic Syndrome, 
Acute renal failure 
Focal segmental glomerulosclerosis 
α Nephrotic Syndrome, 
Acute renal failure 
Focal segmental glomerulosclerosis 
α Nephrotic Syndrome, 
Acute renal failure 
Focal segmental glomerulosclerosis 
α Nephrotic Syndrome, 
Acute renal failure 
Focal segmental glomerulosclerosis 
α Nephrotic Syndrome, Focal segmental glomerulosclerosis 
α −2b Nephrotic Syndrome Focal segmental glomerulosclerosis 
α Nephrotic Syndrome, 
Acute renal failure 
Collapsing Focal segmental glomerulosclerosis 
α Nephrotic Syndrome, 
Acute renal failure 
Collapsing Focal segmental glomerulosclerosis 
α Acute renal failure Collapsing Focal segmental glomerulosclerosis 
β Nephrotic Syndrome Collapsing Focal segmental glomerulosclerosis 
  
 
1.3 Innate immune recognition in the kidney 
 The innate immune system plays a crucial role in disease pathology being the 
first response to pathogens and to tissue injury.  This first line of defense is performed 
via germline-encoded receptors, expressed by macrophages, lymphocytes, dendritic 
cells, monocytes, neutrophils and natural killer cells, among others [163, 164]. These 
receptors, designated as pattern recognition receptors (PRRs), recognize several 
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pathogen-associated molecular patterns (PAMPs) displayed by different bacteria, 
viruses, and parasites, as well as several putative hosts derived endogenous ligands 
(DAMPs) [165-167]. There are several distinct classes of PRRs, including 
transmembrane proteins such as toll-like receptors (TLRs), as well as cytoplasmic 
proteins such as retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and 
nucleotide-binding oligomerization domains containing (NOD)-like receptors (NLRs) 
[168-170] (Figure 7).  
 TLRs are transmembrane receptors characterized by an extracellular domain 
with leucine-rich repeats and a cytoplasmic signaling domain termed the toll-
interleukine 1 receptor (TIR)[171]. According to their localization, these receptors are 
divided into two categories: those expressed on the cell surface (TLR-1, -2,-4,-5,-6,-10,-
11,-12 and 13) mainly recognizing microbial components such as lipids, and those  
found exclusively in intracellular compartments (TLR-3,-7,-8 and -9) recognizing 
microbial nucleic acids [172]. When activated, TLRs trigger intracellular signaling 
pathways via MyD88 (Myeloid differentiation primary response gene 88) or via TRIF ( 
TIR domain containing adapter inducing IFN-β), which culminate in the synthesis of a 
broad range of molecules through the NFkB (nuclear factor kappa-light-chain-enhancer 
of activated B cells) or AP-1 (activator protein 1) pathways [164, 173, 174]. Intrinsic 
renal cells do not express all TLRs. The intracellular receptor for TLR-3 has been 
reported to be expressed in mesangial cells and podocytes, triggering pro-inflammatory 
cytokine production [175, 176]. The LPS receptor TLR-4 is expressed in podocytes 
[177] as well as in tubular cells, which also express TLR-2. Systemic exposure to TLR-
4 and TLR-2 ligands can aggravate kidney diseases, as displayed by the nephrotoxic 
serum nephritis model and by renal ischemia reperfusion injury, both of which primarily 
elicit intra renal cytokine release and glomerular autoantibody production [178, 179].   
The retinoic acid-inducible gene (RIG)-I-like receptors, RIG-I and MDA5, are 
cytosolic receptors for viral RNA and DNA respectively. These receptors are associated 
with mitochondrial-associated adaptor proteins, which interact with the kinases TBK1 
and IKKε. These in turn trigger the phosphorylation of IRFs and induce type I IFN 
production [180, 181].  Kidney biopsies from Lupus patients show co-localization of 
RIG I proteins into the mesangium. Cultured glomerular endothelial cells, mesangial 
cells and tubular epithelial cells express basal levels of RIG-I and MDA5 in culture, 
however the role of these nucleic acid receptors, in regards to intrarenal nucleic acid 
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recognition, is still unclear [182, 183]. Recently, RIG I has been reported to be also 
expressed in glomerular podocytes [175].  
 The cytosolic NLRs include NOD1 and NOD2 (nucleotide-binding 
oligomerization domain1 and 2) receptors that recognize intracellular molecules that 
originate from bacterial infection, like peptidoglycan [184]. When these receptors 
recognize their ligands, they oligomerise and activate NFKB with subsequent 
production of TNF-α and IL-6 [185]. Intrinsic renal expression of NOD receptors has 
been shown in tubular cells, playing a role in sustaining inflammation during IRI [186]. 
 
Figure 7 How pattern recognition receptors induce innate immunity. Several groups of 
extracellular or intracellular innate pattern recognition receptors exist. TLR-1/2/4/5/6 recognizes 
microbes at the cell surface. TLR3/7/8/9 recognize viral and bacterial nucleic acids in 
intracellular endosomes. All TLRs use the intracellular adaptor MyD88 for downstream 
signaling, except for TLR3, which uses TRIF. TLR4 uses MyD88 and TRIF. All TLRs can 
induce the expression of NFkB-dependent genes, including most proinflammatory cytokines and 
chemokines. TLRs also induce the pro cytokines IL-1 and IL-18 (signal 1). These cytokines 
need caspase-1 activation as a second step before they can be released. Caspase-1 activation is 
under the control of the inflammasomes. Type I IFNs represent a separate class of antiviral 
cytokines. Release of type I IFNs is strongest upon recognition of viral nucleic acids via 
TLR3/7/8/9 in endosomes or via cytosolic RNA and DNA receptors. The latter signal via the 
mitochondrial adaptor interferon promotor stimulator 1, but all pathways finally activate the 
transcription factors IRF3/7 for expression of the type I IFNs. (taken from Anders et al., 2011 
[187]) 
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1.3.1 Interferon type I  
 IFN-α and IFN-β central mediators of antiviral immunity and they belong to the 
type I interferon family. These cytokines are specialized in coordinating immunity 
against viruses and other intracellular infections. Type I IFNs are produced by infected 
cells and act in an autocrine and paracrine manner to signal the presence of a viral 
infection [161]. Both IFN-α and IFN-β share a common heterodimeric receptor 
(IFNAR1/2), however they have different properties [188]. Despite the fact that the type 
I IFN receptor is broadly expressed in every organ, type I IFN response has been 
reported to be stronger in liver, kidney and spleen compared to other organs [189]. By 
signaling through the type I IFN receptor, IFNs activate the inducible expression of 
hundreds of genes called ISGs that together establish the ‘‘antiviral state’’ on target 
cells [190-192]. The antiviral state leads to the transcription of various cellular antiviral 
genes coding for host defense proteins. In addition to cell-intrinsic effects that confer 
the antiviral state, IFNs type I regulate the elimination of virally infected cells. The 
IFNs type I system is linked to a variety of effector responses of innate and adaptive 
immunity [161]. Type I IFN activates and regulates natural killer and cytotoxic T cells 
and facilitates dendritic cell cross presentation of viral antigens to CD8+ lymphocytes 
[193]. The mechanisms whereby type I IFNs orchestrate the antiviral adaptive immune 
response are diverse and include the production of chemokines and cytokines that 
positively regulate cytotoxic cell numbers and activities [194, 195]. Plasmacytoid 
dendritic cells are the main type I IFNs producer, however many other cells have been 
reported to produce large amounts of IFNs during viral infection. In the kidney, both 
mesangial and endothelial cells are the major source of intrarenal IFNs production. 
Classically, only collapsing FSGS and lupus nephritis have been directly correlated to 
the type I IFN response, however, there are many other non-viral kidney diseases 
related to type I IFN [181]. Animal studies have documented the functional significance 
of type I IFN in murine models of both lupus nephritis and serum nephritis [196, 197]. 
Type I IFN receptor-deficient mice have been shown to display a marker suppression of 
disease activity in serum nephritis models and genetic mouse models eliciting lupus 
nephritis [198, 199]. Further studies report that augmenting IFN-α release amplifies 
antibody triggered nephritis, contributing to the disease pathology and promoting end-
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organ disease [197]. In contrast, injection of IFN-β has been shown to ameliorate lupus 
nephritis in MRF-Fas-lpr mouse models and in nephritis rat models [200, 201]. 
However, IFN-β, but not IFN-α, has well documented immunosuppressive properties 
[202, 203]. This might explain contradictions in findings between data reported on 
nephritis induced in type I IFN receptor-deficient mice and human data of patients that 
developed FSGS because of IFN α/β therapy. 
 
 In summary, podocyte loss and PEC homeostasis are the major hallmark in the 
pathogenesis of FSGS. Thus, it is necessary to investigate the mechanisms, molecules 
and pathways that promote loss and deregulation of glomerular epithelial cells and their 
progenitors in the context of viral glomerular damage.  IFN-α and IFN-β are potent 
antiviral cytokines, secreted in large amounts during viral infections, which target 
somatic and immune cells. Both of these cytokines have been found to be associated 
with the development of collapsing FSGS. Yet, so far their role in viral 
glomerulonephritis has not been studied in detail. Within the scope of this thesis, the 
role of IFN α/β in FSGS shall be analyzed and discussed. 
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2. Hypotheses 
Based on the above literature, systemic viral infections are frequently associated with 
several kidney diseases. Some viruses cause glomerulopathies also by directly infecting 
glomerular epithelial cells. For example, human immunodeficiency virus (HIV) and 
parvoviruses can infect glomerular epithelial cells, i.e. podocytes and PECs.  Beside the 
clinical relevance of viral glomerulonephritis, little is known about the impact of nucleic 
acid recognition and its consequence (type I IFNs) on glomerular epithelial cells.  
 Therefore we hypothesized that during glomerulonephritis, e.g HIVAN, viral 
replication inside podocytes and PECs would trigger IFN-dependent antiviral responses, 
the process that contributes to glomerular damage. To address this hypothesis we 
employed an in-vitro model of synthetic viral infection using nucleic acid complexes 
with lipofectamine to simulate viral infection in glomerular cells. Furthermore we 
studied the functional impact of nucleic acid on glomerular epithelial cells and their 
progenitors. Once viral nucleic acids reach the intracellular cytosol, they are recognized 
by distinct recognition receptors that induce massive secretion of interferon IFN-α and 
IFN-β. Generally, the induction of IFN-α and IFN-β is a central element of the host`s 
antiviral response. Even though IFN type I receptor deficiency has been reported to 
protect mice from glomerulonephritis [199, 204, 205], other studies have documented 
anti-proteinuric properties of IFN-β in different glomerular diseases model in 
immunocompetent rodents [201] [200].  
 Assuming that in course of viral glomerulopathies the podocytes and PECs are 
exposed to IFN-α and IFN-β, we seeked to elucidate the mechanisms of type I IFNs 
affecting podocyte and PEC homeostasis and decipher whether they exhibit protective 
or detrimental properties. We hypothesized that both IFN-α and IFN-β modulate 
podocytes and PECs homeostasis. To address this hypothesis we first established an in-
vitro study to investigate the effect of both cytokines on podocytes permeability, using 
this parameter to evaluate glomerular filtration barrier. Furthermore we investigated the 
influence of both cytokines on podocyte survival. Next we studied the functional and 
structural impact of both type I IFNs on PECs homeostasis in-vitro, by proliferation, 
migration and differentiation assay.  
 Finally, to validate our in-vitro findings we evaluated the functional role of IFN-
α and IFN-β in an adriamycin-inducing nephropathy model which mirrors FSGS. In 
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order to study the local effect of these cytokines we first established this model in non-
immunocompetent mice (SCID) and later we confirmed our findings in 
immunocompetent mice.  
.  
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3. Material and Methods 
 Instruments and Chemicals 
 
Instruments 
Balance:  
Analytic Balance, BP 110 S Sartorius, Göttingen, Germany 
Mettler PJ 3000 Mettler-Toledo, Greifensee, Switzerland 
 
Cell Incubators: 
 
Type B5060 EC-CO2 Heraeus Sepatech, München, Germany 
 
Centrifuges: 
 
Heraeus, Minifuge T VWR International, Darmstadt, Germany 
Heraeus, Biofuge primo Kendro Laboratory Products GmbH, Hanau, 
Germany 
Heraeus, Sepatech Biofuge A Heraeus Sepatech, München, Germany 
 
ELISA-Reader: 
 
Tecan, GENios Plus Tecan, Crailsheim, Germany 
 
Electric Cell-substrate Impedence 
Sensing 
 
ECIS Applied BioPhisics, New York, USA 
 
Confocal microscopy 
LSM501 META laser 
 
 
 CarlZeiss, Jena, Germany 
 
 
TaqMan Sequence Detection 
System: 
 
ABI prism ™ 7700 sequence 
detector 
PE Biosystems, Weiterstadt, Germany 
  
 35 
 
Other Equipments: 
 
Nanodrop PEQLAB Biotechnology GMBH, Erlangen, 
Germany 
Cryostat RM2155 Leica Microsystems, Bensheim, Germany 
Cryostat CM 3000 Leica Microsystems, Bensheim, Germany 
Homogenizer ULTRA-TURRAX 
T25 
IKA GmbH, Staufen, Germany 
Microtome HM 340E Microm, Heidelberg, Germany 
pH meter WTW WTW GmbH, Weilheim, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Vortex Genie 2™ Bender & Hobein AG, Zürich, Switzerland 
Water bath HI 1210 Leica Microsystems, Bensheim, Germany 
 
3.1.2 Chemicals and reagents 
RNeasy Mini Kit Qiagen GmbH, Hilden, Germany 
RT-PCR primers PE Biosystems, Weiterstadt, Germany 
 
Cell culture: 
 
DMEM-F12 medium Sigma, Munich, Germany 
RPMI-1640 medium GIBCO/Invitrogen, Paisley, Scotland, UK 
FBS 
FBS Hyclone 
EBM 
EGM-MV 
Biochrom KG, Berlin, Germany 
ThermoScientific, UT, USA 
Lonza, Cologne, Germany 
Lonza, Cologne, Germany 
Dulbecco’s PBS (1×) PAA Laboratories GmbH, Cölbe, Germany 
Trypsine/EDTA (1×) PAA Laboratories GmbH, Cölbe, Germany 
Penicillin/Streptomycin (100×) PAA Laboratories GmbH, Cölbe, Germany 
All-trans retinoic acid 
Vitamin 3D 
Antibodies: 
Sigma, Munich, Germany 
Sigma, Munich, Germany 
p21 
CD68  
Santa Cruz Biotechnology, Santa Cruz, CA 
Abcam, Cambridge, UK 
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Claudin-1 
Nephrin 
WT-1 
Invitrogen, Carlsbad, CA 
Santa Cruz Biotechnologies, Santa Cruz, CA 
Santa Cruz Biotechnologies, Santa Cruz, CA 
P-H3 Abcam, Cambrige, UK 
Alexa Fluor 488 anti-rat IgG 
Alexa Fluor 546 anti-rabbit IgG 
Alexa flour 488 anti-goat  
Alexa Fluor 488 anti-mouse IgG1 
Alexa Fluor 546 anti-mouse IgG1 
Invitrogen, Darmstadt, Germany 
Invitrogen, Darmstadt, Germany 
Invitrogen, Darmstadt, Germany 
Invitrogen, Darmstadt, Germany 
Invitrogen, Darmstadt, Germany 
HRP linked Anti-Rabbit secondary  Cell signaling, Danvers, MA 
HRP linked Anti-Mouse secondary  Cell signaling, Danvers, MA 
HRP linked Anti-Goat secondary  Dianova, Hamburg, Germany 
β-Actin Cell signaling, Danvers, MA 
CD3+ AbD Serotec, Düsseldorf, Germany 
 
Elisa Kits: 
 
Mouse Albumin Bethyl Laboratories, TX, USA 
Creatinine FS DiaSys Diagnostic System, GmBH, Holzheim, 
Germany 
 
Chemicals: 
 
Acetone Merck, Darmstadt, Germany 
AEC Substrate Packing Biogenex, San Ramon, USA 
Bovines Serum Albumin Roche Diagnostics, Mannheim, Germany 
 Skim milk powder Merck, Darmstadt, Germany 
DEPC Fluka, Buchs, Switzerland 
DMSO Merck, Darmstadt, Germany 
Diluent C for PKH26 dye Sigma-Aldrich Chemicals, Germany 
EDTA Calbiochem, SanDiego, USA 
30% Acrylamide Carl Roth GmbH, Karlsruhe, Germany 
TEMED Santa Cruz Biotechnology, Santa Cruz, CA 
Eosin Sigma, Deisenhofen, Germany 
Ethanol Merck, Darmstadt, Germany 
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Formalin Merck, Darmstadt, Germany 
Hydroxyethyl cellulose Sigma-Aldrich, Steinheim, Germany 
HCl (5N) Merck, Darmstadt, Germany 
Isopropanol Merck, Darmstadt, Germany 
Calcium chloride Merck, Darmstadt, Germany 
Calcium dihydrogenphosphate Merck, Darmstadt, Germany 
Calcium hydroxide Merck, Darmstadt, Germany 
MACS-Buffer Miltenyl Biotec, Bergisch Gladbach, Germany 
Beta mercaptoethanol Roth, Karlsruhe, Germany 
Sodium acetate Merck, Darmstadt, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium citrate Merck, Darmstadt, Germany 
Sodium dihydrogenphosphate Merck, Darmstadt, Germany 
Penicillin Sigma, Deisenhofen, Germany 
Roti-Aqua-Phenol Carl Roth GmbH, Karlsruhe, Germany 
Streptomycin Sigma, Deisenhofen, Germany 
Tissue Freezing Medium Leica, Nussloch, Germany 
Trypan Blue Sigma, Deisenhofen, Germany 
Oxygenated water DAKO, Hamburg, Germany 
Xylol Merck, Darmstadt, Germany 
Miscellaneous:  
Cell death detection (TUNEL) kit Roche, Mannheim, Germany 
Microbeads Miltenyl Biotech, Germany 
Cell Titer 96 Proliferation Assay  Promega, Mannheim, Germany 
LS+/VS+ Positive selection 
columns 
Miltenyl Biotec, Bergish Gladbach, Germany 
Preseparation Filters Miltenyl Biotec, Bergish Gladbach, Germany 
Super Frost® Plus microscope 
slides  
Menzel-Gläser, Braunschweig, Germany 
Needles BD Drogheda, Ireland 
Pipette’s tip 1-1000µL Eppendorf, Hamburg, Germany 
Syringes Becton Dickinson GmbH, Heidelberg, Germany 
Plastic histocasettes NeoLab, Heidelberg, Germany 
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Tissue culture dishes Ø 100x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes Ø 150x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes Ø 35x10mm Becton Dickinson, Franklin Lakes, NJ, USA 
Tissue culture flasks 150 cm2 TPP, Trasadingen, Switzerland 
Tubes 15 and 50 mL TPP, Trasadingen, Switzerland 
Tubes 1.5 and 2 mL TPP, Trasadingen, Switzerland  
All other reagents were of analytical grade and are commercially available from 
Invitrogen, SIGMA or ROTH. 
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3.1 In-vitro methods 
 
3.1.1 Isolation and cultured of human renal progenitors CD24+CD133+ 
 Renal progenitor cells were characterized and isolated from human renal 
biopsies as described [206]. In brief, kidney biopsies were processed and sieved for 
isolating glomeruli (60, 80, and 150 mesh). During this process the glomeruli were 
separated from the tubules through graded mesh screening. To enrich the number of 
capsulated glomeruli non-enzymatic digestion was performed. The glomerular 
suspension was collected and plated on fibronectin-coated dishes (10 µg/ml; Sigma-
Aldrich).  After 4 to 5 days in culture, isolated glomeruli adhered to the plate, resulting 
in cellular outgrowth. Glomeruli were detached, and the cellular outgrowth was cultured 
as a bulk.  The cells were cultured with EGM-MV 20% FBS (Hyclone, Logan, UT) 
media and they were checked for simultaneous expression of CD133 and CD24 by flow 
cytometer analysis. Generation of clones from CD24+CD133+ PECs was performed by 
limiting dilution in fibronectin-coated 96-well plates in EGM-MV 20% FBS. 
CD24+CD133+ PECs were also maintained in culture as a bulk, and routine cell 
passaging was performed. All the experiments were performed using cells at least at 
passage 3. Cells were grown at 37 0C supplied with 5 % CO2. Trypsin and EDTA (1:1 
vol/vol) was used for splitting the cells. Cells were counted using Neubauer’s chamber 
and the desired number of cells were used for experiments. 
 
 
3.1.2 In-vitro differentiation of human renal progenitors towards mature podocytes 
 To induce their differentiation towards podocytes, CD133+CD24+ PECs were 
seeded at 70% confluence and culture without FBS for a minimum of 4 h. The medium 
was replaced with a differentiation medium (VRADD) containing DMEM-F12 (Sigma, 
Munich, Germany) supplemented with 5% FBS (Hyclone, Thermo Scientific, UT, 
USA), vitamin D3 100 nM (Sigma, Munich, Germany), and all-trans retinoic acid 100 
µM (Sigma, Munich, Germany); and dexamethasone 0,1 µM (Sigma, Munich, 
Germany) for 48h as described [105, 117] (Figure 8). After 48h the VRADD medium 
were removed and changes in changing of shape was observed and de novo expression 
  
 40 
of podocytes marker was evaluated by real time PCR analysis. Human renal progenitors 
cultured with EGM-MV 20% FBS were use as control for morphological and molecular  
 
Figure 8. To induce their differentiation towards podocytes, CD133+CD24+ PECs were seeded 
at 70% confluence and culture without a differentiation medium (VRADD) containing DMEM-
F12 supplemented with 5% FBS, vitamin D3 100 nM, and all-trans retinoic acid and 
dexamethasone for 48h. Human renal progenitors cultured with EGM-MV 20% FBS were use 
as control as described. After 48h the VRADD medium were removed and morphological 
changes were observed (C-D) compared to the controls (A-B). 
analysis to verify the success of the in-vitro differentiation. To evaluate the complete 
differentiation, gene expression for podocyte marker nephrin was performed. 
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3.1.3 Culture of immortalized murine parietal epithelial cell and podocyte cell lines  
 Immortalized mouse parietal epithelial cells (mPECs) were isolated and 
characterized from preparations of mouse glomeruli as described [207]. mPECs were 
kept in culture at 33 °C on 10 cm  plates (BD Biosciences, Heidelberg, Germany) 
coated with type I collagen, in RPMI1640 containing 5% FBS, 1mM Pyruvate 
(GIBCO/Invitrogen, Paisley, Scotland UK),10mM HEPES (GIBCO/Invitrogen, Paisley, 
Scotland UK), 0,0075% Sodium Bicarbonate (GIBCO/Invitrogen, Paisley, Scotland 
UK), and 50 U/ml IFN-γ (Roche,  Munich, Germany) as described [207]. Under these 
conditions, the cells are able to grow due to the activation of the SV40 promoter, which 
is thermo sensitive (33°C) and regulated by the IFN-γ presence. Immortalized mouse 
podocytes (MPCs) were isolated and cultured at 33 °C on 10 cm plates (BD 
Biosciences, Heidelberg, Germany) coated with type I collagen, in RPMI1640 
containing 50 U/ml IFN-γ as described.[208]. To induce their differentiation, mPECs 
and MPC were cultured under growth-restrictive conditions (at 37 °C, in absence of 
IFN-γ) for 14 days.  Under growth restrictive conditions the SV40 promoter is switched 
off, allowing the cells to stop to replicate and to display a differentiated phenotype.  
After two weeks in culture under restrictive growth conditions, fully differentiated 
mouse parietal epithelial cells (mPECs) displayed a polygonal shape together with 
claudin marker expression; podocytes displayed an arborized shape expressing 
synaptodin. Cells exhibiting these features were used to perform all the experiments. 
 
 
3.1.4 Cell freezing and thawing 
 At earlier passages large amounts of cells were grown under standard culture 
conditions and were frozen for future use. Cells to be frozen were detached from the 
culture plates and counted using Neubauer’s chamber. One million (106) of cells were 
centrifuge under sterile conditions for 5 min at 1000 RPM. The cell pellet was 
maintained on ice and carefully re-suspended in cold freezing medium (90 % respective 
culture medium and 10 % DMSO) by pipetting the suspension repeatedly up and down. 
1 ml aliquots were quickly dispensed into freezing vials. The cells were located in the 
freezing chamber at –800C overnight. The next day, all aliquots were transferred to 
liquid nitrogen.In order to thaw cells a frozen vial was removed from liquid nitrogen 
and put in a water bath at 37 0C for 5 min. The cells were then re-suspended in 10 ml of 
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warm complete growth medium and transferred to new culture plates.  After 12 h the 
cells were observed under the microscope and the medium was changes once more. 
 
 
3.1.5 Proliferation assay 
 Human CD24+CD133 PECs where counted and seeded in 96 well plates (2500 
cells/well). Full differentiated mPECs where seeded in a collagen I coated 96 well 
plates at a density of 5000 cells/well. Cells were cultured in absence of FBS for 
minimum 4 h to synchronize all the cells in the same cell cycle phase and then 
stimulated with medium or dsDNA complexes with lipofectamine or human IFN-α 
(5000 U/ml) or mouse IFN-β (5000 U/ml) respectively. Proliferation was determinate 
using microtetrazolium assay (MTT assay, Promega) according to the manufacturer 
instructions. The assay is based on the cellular conversion of a tetrazolium salt into a 
formazan product, according to the metabolic state of the cells. In Brief, 15 µl of dye 
solution (tetrazolium) was added in each well and the plate incubated for 4h at 37 °C in 
the dark. After 4 h the cells where observed under the microscope and intracellular dark 
crystals of formazan were detected. The reaction was stopped adding 100 µl of stop/ 
solubilization solution and the plate was incubated over night at room temperature. The 
next day the absorbance was recorded at 570 nm using a 96-well plate reader (TECAN-
Genios Plus) 
 
 
3.1.6 Migration assay 
 Human and murine PECs migration was determined using silicone inserts with a 
defined cell-free gap. (Ibidi, Munich, Germany). The inserts were placed on 12 wells 
and the cells were seeded at 100% confluence in both culture insert wells. After 24h the 
insert was removed and the cells were stimulated with medium, mouse IFNα/β  (5000 
U/ml) or human IFNα/β  (5000 U/ml). To evaluate the cell migration rate, pictures of 
the wound were taken at 0h and every 3h on a digital phase contrast microscope. For 
each stimulation and time point, over 8 pictures of different spots were taken and then 
analyzed on our digital image analysis software (Photoshop Extended CS5 Software, 
Adobe Software, US). Two lab members independently performed digital image 
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analysis in order to minimize the possibility of cognitive bias. Change in wound sizes 
between two time points expressed the extent of healing in our experiment. 
 
 
3.1.7 Flow cytometry   
 In order to study cell death, AnnexinV/PI assay was performed and analyzed 
using flow cytometry. Cells cultured with medium, human IFNα/β (5000 U/ml) or 
mouse IFNα/β (5000 U/ml), were detached and counted using Neubauer’s chamber. 
Cell suspensions from the stimulation experiment together with supernatant, were 
prepared and washed two times with AnnexinV /PI buffer (140 mM NaCl, 4 mM KCl, 
0.75 mM MgCl2 and 10 mM HEPES in ddH20). After centrifugation, the pellet was re-
suspended by pipetting the suspension repeatedly up and down in 100 µl of mix 
containing labeled annexin V (5µl) and PI(5µl) in Annexin V /PI buffer . The cells were 
incubated for 15 min in dark at room temperature. After the incubation, the cells were 
analyzed by flow cytometry using a FACScalibur machine. 
 
 
3.1.8 Cell cycle analysis assay 
In order to study cell cycle progression and cell death, PI staining was performed 
and analyzed using flow cytometry. Cells cultured with medium, human IFNα/β (5000 
U/ml) or mouse IFNα/β (5000 U/ml), were detached and counted using Neubauer’s 
chamber.  500000 cells from the stimulation experiment were collected and washed two 
times with PBS. After centrifugation, the pellet was re-suspended by pipetting the 
suspension repeatedly up and down in 100 µl solution, containing 50% FBS and 50% 
PBS. Then 300 µl of cold 70% ethanol was added (drop-wise) and the cellular 
suspensions were incubated for 24h at 4°C. After incubation, the pellets were washed 
two times with PBS and re-suspended with 100 µl of ma mix containing 50µg/ml PI and 
100U/ml of RNAase. The cells were incubated for 30 min in dark at room temperature. 
After the incubation, the cells were analyzed by flow cytometry using a FACScalibur 
machine. 
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3.1.9 In-vitro assessment of podocyte detachment 
 Differentiated human and murine podocytes were cultured with medium or 
human IFNα/β (5000 U/ml) or mouse IFNα/β (5000 U/ml) respectively. After 24h of 
stimulation, the total number of attached and detached (in the supernatant) cells was 
evaluated by using Neubauer’s chamber. In addition, detached podocytes in the 
supernatant were stained with PI 100 µl of mix containing PI (5µl) in annexin V /PI 
buffer and analyzed by flow cytometry. The amount of detached cells was determined 
as percentage of PI + cells found in the supernatant over the total number of cells 
(attached cells + detached cells). 
 
 
3.1.10 Electric cell impedance sensing assay (ECIS) 
 IFNα/β induced changes in podocyte resistance and capacitance were analyzed 
using an ECIS device (Applied Biophysics, Troy, USA). The ECIS device is based on 
alternate current (AC) impedance measurements, using a weak and non-invasive AC 
signals [209, 210]. Detachment or spreading of cells on the electrode surface change the 
resistance in a way that morphological information can be inferred.  The measurement 
system consists of an eight-well cell culture dish with electrodes deposited upon the 
bottom of each well, a lock-in amplifier with an internal oscillator, relays to switch 
between the different wells, and a personal computer that controls the measurement and 
stores the data [209]. During the experiment the current flow is approximately constant 
(1µM) and the voltages across the system are measured by the amplifier and converted 
to the components of the electrode impedance, which are presented formally as 
resistance and capacitance of a resistor-capacitor series circuit.  The data are as a 
function of time in frequency scan mode, in which the impedance is measured at 
different frequencies between 10 and 100000 Hz [209]. Murine primary podocytes were 
isolated and cultured as described [211]. Cells were seeded on ECIS culture-ware 
(80BW10E+, Applied Biophysic) that was pre-incubated with podocyte cell medium 
overnight and connected to the ECIS device. Confluent podocytes were kept overnight 
at 37 °C and 5% CO2 before medium was exchanged to HBSS +/- IFNα/β or solvent. 
Resistance (Ω) was analyzed for 30 min at 400 Hz or 40Hz, respectively. 
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3.2 Protein isolation and western blotting 
3.2.1 Protein isolation 
 Proteins from cell culture were extracted using RIPA buffer (50 mM Tris HCl, 
pH 7.5; 150 mM NaCl; 100 µM sodium orthovanadate, 0.5 % sodium deoxycholat, 4 % 
NP-40, 2 % Triton-X-100; 5 mM EDTA; 300 mM sucrose), (Sigma, Germany) 
containing protease inhibitor tablets COMPLETE (Roche, Mannhein, Germany) In 
brief, cells were detached mechanically (in absence of trypsin) in Ripa Buffer 
containing protease inhibitor. All steps were performed at 4°C to avoid protein 
degradation. The lysates were collected and maintained at constant agitation for two h at 
40C. The samples were then centrifuged for 20 min at 12000rpm at 4 0C to remove the 
cell membrane. The pellet was discarded and the supernatant collected in a fresh tube. 
Protein estimation was performed using Bradford´s assay (Biorad).  
 
 
3.2.2 Western blotting 
 From each sample, 50µg of the protein was mixed with 5x SDS loading buffer 
(100 mM Tris-HCl, 4% SDS, 20% glycerol, and 0.2% bromo-phenol blue) and heated at 
95°C for 5 min. Proteins were separated by SDS PAGE and subsequently transferred to 
an methanol-activated PVDV Immobilon-P membrane (Millipore, Eschborn, Germany) 
using the BioRad Semi-Dry Blotting System (BioRad, Munich, Germany). Electro 
transfer was performed for 1 h at 25V. After the transfer, the membrane was stained for 
10 min in Ponceau solution (0.5 % Ponceau S in 1 % acetic acid) and de-stained with 
H2O to verify successful transfer of protein and note the position of the marker 
(peqGOLD protein marker; PeqLab, Erlangen, Germany. After blocking for 1hr at room 
temperature with 5% milk in Tris-buffered saline buffer (20 mM Tris-HCl, 150 mM 
NaCl, and 0.1% Tween 20), the membranes were then incubated overnight at 4°C with 
primary antibodies and kept in constant agitation to enhance binding.  After washing, 
the membrane was incubated with respective secondary antibodies in Tris buffered 
saline buffer for one hour at room temperature. The signals were visualized by an 
enhanced chemiluminescence system (Amersham, Buckinghamshire, UK). 
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3.3 RNA analysis 
3.3.1 RNA isolation from cells and tissue 
  At the end of the experiment, cells were harvested under sterile conditions for 
RNA isolation. Immediately after kidney isolation, a small piece of kidney from each 
mouse was preserved in RNA-later and stored at -200C until processed for RNA 
isolation. RNA isolation was performed using RNA isolation kit from Ambion 
(Ambion, CA, USA) according to the protocol provided. The harvested cells were 
washed two times with sterile PBS and centrifuged. The supernatant was discarded and 
the pellet was re-suspended in 350 µl lysis buffer containing 10µg/ml β-
mercaptoethanol and frozen at –80 °C until RNA isolation. Tissues (30 mg) preserved 
in RNA-later were homogenized using blade homogenizer for 30 seconds at 4 °C in 
lysis buffer (600 µl) containing β-mercaptoethanol (10 µl/ml).  During RNA isolation 
the samples thawed and 350 µl of 70 % ethanol made from 1% diethyl pyrocarbonate 
treated water (DEPC water) was added to the samples and mixed well. This mixture was 
then loaded onto RNeasy mini columns held in 2 ml collection tubes and centrifuged at 
12000 xg for 15 seconds. The flow-through was discarded and the columns were loaded 
with 700µl of Wash buffer I and centrifuged at 12000 xg for 15 seconds. The collection 
tubes were discarded together with the flow-through and the columns were transferred 
to fresh 2 ml collection tubes.500 µl of Wash Buffer II was pipetted onto the column 
and centrifuged at 12000 x g for 15 seconds, and the flow-through was discarded. This 
step was repeated and the column was rendered dry by centrifugation and placed in a 
1,5 ml fresh collection tube. Then, 40 µl of RNase free water was pipetted directly on 
the silica-gel membrane and was centrifuged to collect the RNA solution. Isolated RNA 
was measured, checked for purity and stored at -800C. 
 
 
3.3.3 RNA quantification and purity check 
 The isolated RNA samples were quantified using Nano drop (PEQLAB 
Biotechnology GMBH, Erlangen, Germany). The ratio of optical densities at 260 nm 
and 280 nm is an indicator for RNA purity (indicative of protein contamination in the 
RNA samples). Only samples with a ratio of 1.8 or more were considered to be of 
acceptable quality. 
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3.3.4 cDNA synthesis and real-time PCR 
 The RNA samples, isolated according to procedures detailed above, were 
processed for cDNA conversion using reverse transcriptase II (Invitrogen, Karlsruhe, 
Germany). RNA samples were diluted in DEPC water to a concentration of 2 µg / 30 µl. 
A master mix was prepared with the following reagents: 9 µl of 5 x buffer (Invitrogen, 
Karlsruhe, Germany), 1µl of 25mM dNTP mixture (Amersham Pharmacia Biotech, 
Freiburg, Germany), 2 µl of 0.1 M DTT (Invitrogen, Karlsruhe, Germany), 1 µl of 40 
U/µl RNasin (Promega, Mannheim, Germany), 0.5 µl of 15 µg/ml linear acrylamide 
(Ambion Ltd, 36 Cambridgeshire, UK), 0.5 µl of Hexanucleotide (Roche, Mannheim, 
Germany), 1 µl of Superscript (Invitrogen, Karlsruhe, Germany) or ddH2O as a control. 
The master mix was made to a volume of 13,2 µl and added to 1 µg / 20 µl RNA 
samples were taken in separate DEPC treated microcentrifuge tubes, which were mixed 
and placed at 42 °C on a thermal shaker incubator for 1 hour. After 1 hour the cDNA 
samples were collected and placed at -20 °C until use for RT-PCR analysis.  
 
 
3.3.5 Real time PCR 
  The cDNA samples prepared as described above were diluted 1:10 for real-time 
polymerase-chain-reaction (RT-PCR). 2 µl of diluted cDNA samples was mixed with 
SYBR green master mix (10 µl), forward primer (0.6 µl) and, reverse primer (0.6 µl), 
both specific for the gene of interest, Taq polymerase (0.16 µl) and distilled water (6.64 
µl). The RT-PCR was performed using Light Cycler480. Pre-incubation was carried out 
for 5 min at 95 0C so as to activate the polymerase and complete de-naturation of cDNA 
samples. Then the cDNA was amplified for 45 cycles, each comprising of 15 seconds 
incubation at 95 0C and 45 seconds incubation at 60 0C. The melting curve was set for 
initial 95 0C for 5 seconds followed by 65 0C for 1 min with continuous heating. The 
RT-PCR of the reference gene (18S rRNA) was carried out under similar conditions. 
The CT values were calculated using the Light Cycler480 and the results were 
normalized with respect to the reference gene expression. In all cases controls 
consisting of ddH2O were negative for target or reference genes. All designed SYBR 
green primers for all genes evaluated were obtained from Metabion (Metabion, 
Martinsried, Germany). 
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Table 5. Murine oligonucleotide primers used for SYBR-Green RT-PCR 
Gene Sequence  
18s forward:  5’ GCAATTATTCCCCATGAACG 3’ 
reverse: 3’ AGGGCCTCACTAAACCATCC 5’ 
mIFIT1 
 
forward: 5’CAAGGCAGGTTTCTGAGGAG 3’ 
reverse: 3’ GACCTGGTCACCATCAGCAT 5’ 
mIFIT3 
 
forward: 5’ TTCCCAGCAGCACAGAAAC 3’ 
reverse: 3’ AAATTCCAGGTGAAATGGCA 5’ 
mMX1 forward: 5’ TCTGAGGAGAGCCAGACGAT 3’ 
reverse: 3’ CTCAGGGTGTCGATGAGGTC 5’ 
mCXCL10 forward: 5’ GGCTGGTCACCTTTCAGAAG 3’ 
reverse: 3’ ATGGATGGACAGCAGAGAGC 5’ 
mPUMA forward: 5’ CACCTAGTTGGGCTCCATTT 3’ 
reverse: 3’ ACCTCAACGCGCAGTACG 5’ 
mBAK forward: 5’ AGACCTCCTCTGTGTCCTGG 3’ 
reverse: 3’ AAAATGGCATCTGGACAAGG 5’ 
mBID forward: 5’ GTGTAGCTCCAAGCACTGCC 3’ 
reverse: 3’ GCAAACCTTTGCCTTAGCC 5’ 
mBAX forward: 5’ GATCAGCTCGGGCACTTTAG 3’ 
reverse: 3’ TTGCTGATGGCAACTTCAAC 5’ 
mTNFα forward: 5’ AGGGTCTGGGCCATAGAACT 3’ 
 reverse: 3’ CCACCACGCTCTTCTGTCTAC 5’ 
mIL6 forward: 5’ TGATGCACTTGCAGAAAACA 3’ 
 reverse: 3’ ACCAGAGGAAATTTTCAATAGGC 5’ 
mCXCL9 forward: 5’CCTAGTGATAAGGAATGCACGATG 3’ 
 reverse: 3’ CTAGGCAGGTTTGATCTCCGTTC 5’ 
mCXCL11 forward: 5’ CCGAGTAACGGCTGCGACAAAG 3’ 
 reverse: 3’ CCTGCATTATGAGGCGAGCTTG 5’ 
mIFNR1 forward: 5’ CCAAGGCAAGAGCTATGTCCTG 3’ 
 reverse: 3’ CAGTGCGTAGTCTGGACATTTGC 5’ 
mIFNR2 forward: 5’ GAGCCTAGAGACTATCACACCG 3’ 
 reverse: 3’ TACCAGAGGGTGTAGTTAGCGG 5’ 
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 Table 6. Human oligonucleotide primers used for SYBR-Green RT-PCR 
Gene Sequence  
18s forward: 5’ GCAATTATTCCCCATGAACG 3’ 
reverse: 3’ AGGGCCTCACTAAACCATCC 5’ 
hIFIT1 
 
forward: 5’ ATCCAGGCGATAGGCAGAGATC 3’ 
reverse: 3’ GCCTTGCTGAAGTGTGGAGGAA 5’ 
hIFIT3 
 
forward: 5’ CCTGGAATGCTTACGGCAAGCT 3’ 
reverse:     3’ GAGCATCTGAGAGTCTGCCCAA 5’  
hMX1 forward: 5’ GGCTGTTTACCAGACTCCGACA 3’  
reverse: 3’ CACAAAGCCTGGCAGCTCTCTA 5’ 
hCXCL10 forward: 5’ GGTGAGAAGAGATGTCTGAATCC 3’  
reverse: 3’ GTCCATCCTTGGAAGCACTGCA 5’ 
hPUMA forward: 5’ ACGACCTCAACGCACAGTACGA 3’ 
reverse: 3’ CCTAATTGGGCTCCATCTCGGG 5’ 
hBAK forward: 5’ TTACCGCCATCAGCAGGAACAG 3’ 
reverse: 3’ GGAACTCTGAGTCATAGCGTCG 5’ 
hBID forward: 5’ TGGGACACTGTGAACCAGGAGT 3’ 
reverse: 3’ GAGGAAGCCAAACACCAGTAGG 5’ 
hBAX forward: 5’ TCAGGATGCGTCCACCAAGAAG 3’ 
reverse: 3’ TGTGTCCACGGCGGCAATCATC 5’ 
hIFNR1 forward: 5’ CGCCTGTGATCCAGGATTATCC 3’ 
 reverse: 3’ TGGTGTGTGCTCTGGCTTTCAC 5’ 
hIFNR2 forward: 5’ ACCGTCCTAGAAGGATTCAGCG 3’ 
 reverse: 3’ CCAACAATCTCAAACTCTGGTGG 5’ 
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3.4 Experimental procedures 
3.4.1 Animals 
 Combined Immunodeficient (BALB/cJHan™Hsd-Prkdcscid) mice 
obtained from Harlan, Udine, Italy.  The experiments were performed in Italy 
according to the Italian animal care and were approved by local government 
authorities. Balb/c mice were obtained from Charles river, Germany. The 
experiments were performed in Germany according to the German animal care 
and were approved by the Regierung von Oberbayern. All mice were kept under 
sterile housing conditions under a 12h light and dark cycle. Water and standard 
chow (Ssniff, Soest, Germany) were available ad libitum for the complete 
duration of the study. Cages, bedding, nestles, food, and water were sterilized by 
autoclaving before use.  
 
 
3.4.2 Adriamycin-induced nephropathy and type I IFN treatment 
 Adriamycin nephropathy was induced in 6-week old female mice by a 
single i.v injection of adriamycin on day 0. The dose of 6,5 mg/kg body weight in 
phosphate buffered saline PBS, Sigma) was used to induce nephropathy in SCID 
mice; dose of 11,5 mg/kg body weight in phosphate buffered saline PBS (Sigma) 
was used to induce nephropathy in Balb/c mice. Mice received daily subcutaneous 
injections of either saline (vehicle), IFN-α6 (1000 U) or IFN-β (1000 U). Group 
size was n=6 in each experiment, and each experiment was repeated three times.  
After 7 days plasma and urine samples were collected before sacrifice by cervical 
dislocation and afterwards kidney tissues were harvested. The harvested kidney 
tissues were divided into three parts each. One part was immediately flash frozen 
in liquid nitrogen and then further stored at -800C for protein isolation and cryo 
sections, the second part was collected in RNA later solution (Ambion, CA, USA) 
and stored at -200C for RNA isolation and the third part of the kidney was kept in 
formalin to fix the tissue before embedding in paraffin for histological analysis.  
All experimental procedures were performed according to the German and the 
Italian animal care and ethics legislation and had been approved by the local 
government authorities. 
  
 51 
 
 
3.4.3 Blood and urine sample collection 
 Urine sample were collected using metabolic cages. Animals were kept in 
metabolic cages in absence of food for 12 h to enhance sample collection. 
Collected urine was stored at -200C until used for further biochemical analysis. At 
the end of the study blood samples were collected by retro-orbital bleeding 
technique, under isoflurane anesthesia, in microcentrifuge tubes containing EDTA 
(10µl of 0.5 M solution per 200µl of blood). Samples were centrifuged at 8000 
rpm for 5 min and plasma was separated and stored at -200C until used for 
analysis.  
 
 
3.5 Urinary albumin to creatinine ratio 
3.5.1 Urinary albumin 
 Urinary albumin levels were determined using Albuwell M kit from 
Exocell (Philadelphia, PA, USA) following manufacturer’s instructions. Albuwell 
M is an indirect competitive ELISA designed to monitor urinary albumin. In the 
assay procedure, sample and rabbit anti-murine albumin antibody are added to 
albumin-coated wells. The antibody interacts and binds with the albumin 
immobilized to the stationary phase or with albumin in the fluid phase, hence the 
notion of competitive binding. Generally, albumin levels in urine samples from 
FSGS mice were quite high, so that urine samples were diluted 300 to 1500 times 
with EIA diluent (provided by the kit) before estimation. In short, diluted 
sample/standard and rabbit anti-murine albumin were added in the respective well 
of the pre-coated plate and incubated at room temperature for 30 min. After 
incubation, each well was washed 10 times with wash buffer (0.15 M NaCl, 0.01 
M triethanolamine (pH 6.8), 0.05% Tween 20, and 0.05% Proclin 300). Anti-
rabbit HRP conjugate detection antibody) was added and the plate was incubated 
in dark for further 30 min. After HRP-conjugate incubation, each well was 
washed 10 times with wash buffer and TMB reagent (freshly prepared by mixing 
equal volumes of two substrate reagents) was added and incubated in dark until 
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color reaction was completed followed by addition of stop solution (2 M H2SO4). 
The absorbance was read at 450 nm within 10 min of adding stop solution. The 
albumin content in each sample was determined using the equation of regression 
line generated by plotting absorbance of different standards against their known 
concentrations.  
 
 
3.5.2 Urinary creatinine assay kit  
 Urinary creatinine and plasma creatinine levels were measured using 
Jaffe´s enzymatic reaction using a Creatinine FS kit (DiaSys Diagnostic system, 
GmBH, Holzheim, Germany). Urine samples were diluted 10 times with distilled 
water. Different dilutions of standard were prepared using the stock provided with 
the kit. Working mono reagent was prepared by mixing 4 parts of reagent 1 (R1) 
and 1 part of reagent 2 (R2) provided with the kit. Then, 10 µl of each diluted 
sample and standard was added to a 96 well plate with flat bottom (Nunc 
maxisorb plate). The mono reagent (200µl) was added to each well, and 
immediately after 1 minute of incubation, the absorbance of the reaction mixture 
was measured at 492nm using an ELISA plate reader. This was repeated at 1 and 
2 min of additional incubation. The change in absorbance (Δ A) was calculated as 
Δ A = [(A2 – A1) sample or standard] – [(A2 – A1) blank]. And creatinine 
content of samples was calculated as: 
Creatinine (mg/dl) = ΔA sample /ΔA standard * Concentration of standard 
(mg/dl) 
Urinary albumin to creatinine ratio was calculated after converting values for 
albumin and creatinine to similar units (mg/dl). Albumin content for each sample 
calculated (mg/dl) was divided by creatinine content (mg/dl) for the same sample. 
 
 
3.6 Periodic acid Schiff staining 
 For immunohistological studies one part of each kidney from each mouse 
was fixed in formalin (10 % in PBS or Saline) over night and processed using 
tissue processors (Leica) and paraffin blocks were prepared. Formalin-fixed 
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tissues were processed using tissue processors (Leica) and paraffin blocks were 
prepared. 2 µm thick paraffin-embedded sections were cut. De-paraffinization was 
carried out using xylene (3 * 5 min) followed by re-hydration by incubating the 
sections in 100% absolute ethanol (3 * 3 min), 95% ethanol (2 * 3 min) and 70% 
ethanol (1 * 3 min) followed by washing with distilled water (2 * 5 min). Re-
hydrated sections were incubated with Periodic acid (2 % in distilled water) for 5 
min followed by washing with distilled water (1* 5 min). Then sections were 
incubated with Schiff solution for 20 min at room temperature followed by 
washing with tap water (1* 7 min) and counter staining with Hematoxylin 
solution (1* 2 min). This was followed by washing with tap water (1* 5 min) and 
finally sections were dipped in alcohol 90% and dried and closed with cover slips. 
 
 Mac2 staining 
 Number of infiltrated macrophages in glomeruli was counted in sections 
stained with Mac2 (pan marker for macrophage) antibodies. Mac2 positive cells 
per glomerulus were counted manually in 25 glomeruli for each section and were 
presented as mean ± standard error of mean for respective groups 
 
CD3 staining 
 Number of infiltrated lymphocytes in glomeruli was counted in sections 
stained with CD3 (pan marker for lymphocytes) antibodies. CD3 positive cells per 
glomerulus were counted manually in 25 glomeruli for each section and were 
presented as mean ± standard error of mean for respective groups 
 
 
3.7 Immunostaining and Confocal imaging 
 All immunofluorescent studies were performed on five micrometer-thick 
frozen sections and analyzed with a LSM510 META laser confocal microscope 
(Carl Zeiss, Jena, Germany). Five µm thick frozen sections were cut and fixed in 
in cold formalin (4 % in PBS or Saline) for 20 min and washed for 5 min in PBS. 
Specific blocking buffer prepared in PBS+ 3% BSA+ diluted serum host of the 
secondary antibody, was added and sections were incubated for 30 min at room 
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temperature. The sections were incubated with diluted primary antibody for 15 
min at 37°C followed by 1 h at 4 °C. After 5 min in PBS, 200µl of specific 
secondary antibody (diluted 1:1000) was added and the section incubated for 30 
min in the dark at room temperature. At the end of the incubation with the 
secondary antibody the sections were washed for 5 min followed by the second 
staining performed as previously described. The nuclei staining were performed 
using TOPRO. The following primary antibodies were used: anti CD68 mAb 
(clone FA-11, Abcam, Cambridge, UK), anti-claudin-1 mAb (clone 2H10D10, 
Invitrogen, Carlsbad, CA), anti-nephrin (clone C17, Santa Cruz Biotechnologies, 
Santa Cruz, CA), anti-WT-1 (clone F-6, Santa Cruz Biotechnologies, Santa Cruz, 
CA); anti-H3-Ser10 (anti-phospho histone H3, Abcam, Cambridge, UK), anti-
podocin (anti-NPHS2 Abcam). Double immunolabeling was performed using the 
following secondary antibody: Alexa Fluor 488 goat anti rat IgG (Invitrogen, Life 
Technologies GmbH, Darmstadt, Germany), Alexa Fluor 546 goat anti rabbit IgG 
(Invitrogen), Alexa flour 488 rabbit and goat IgG (Invitrogen), Alexa Fluor 546 
goat anti mouse IgG1 (Invitrogen), Alexa Fluor 488 goat anti mouse IgG1 
(Invitrogen). Double positive cells were quantified in 15 glomeruli of at least six 
sections for each mouse by two independent and blinded observed 
 
 
3.8 Light and transmission electron microscopy  
 Light and transmission electron microscopy of 164 consecutive renal 
biopsies (2011-2012) from the Department of Pathology, Washington University, 
School of Medicine, St Louis, MO plus three selected cases of HIV+ collapsing 
FSGS (previously called HIV-associated nephropathy were performed. Renal 
biopsies were fixed in 10% formalin, 2% glutaraldehyde and frozen in liquid 
nitrogen for light-microscopy. Tissue for transmission electron microscopy was 
rinsed in phosphate buffer (0.1 M, pH 7.2), post-fixed in l% osmium tetroxide, 
dehydrated in graded alcohols and propylene oxide, and embedded in Polybed 812 
(Polysciences). Ultrathin sections were stained with 2% aqueousmagnesium 
uranyl acetate for 30 min and then by lead citrate for 5 min. A JEOL JEM 100 
CXanalytical TEMSCAN electron microscope was used at 60 kv. The sections 
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were retrospectively reviewed searching for abnormal mitoses and or 
multinucleated podocytes.  
 
 
3.9 Statistical analysis 
  Statistical analysis was performed using GraphPad prism 5 Software 
(GraphPad Software, USA). Data are presented as mean ±SEM/SD. For multiple 
comparison of groups one-way ANOVA was used followed by post-hoc 
Bonferroni`s test. Paired Student`s t-test was used for the comparison between 
two groups. A value of p < 0.05 was considered as statistically significant.  
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4. Results 
4.1 Glomerular epithelial cells express IFNR 
 The expression of both IFN I receptor chains (IFNAR1 and IFNAR2) was 
tested by RT-PCR, in podocytes as well as in PECs from human and murine 
origin. Glomerular podocytes and PECs were cultured for 12 h with IFNα/β . 
mRNA was isolated for real time  PCR analysis. Epithelial glomerular cells from 
both species showed a basal expression of IFN I receptor. Upon type I IFN 
stimulation, PECs and podocytes from both species did not show increased 
expression of the IFNR1 and IFNR2 chains (Figure 9).  
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Figure 9. Glomerular parietal epithelial cell and podocyte express both IFN receptor 
chains.  Glomerular podocyte and PECs mRNA from human (A, C) and mouse (B, D) 
was isolated after 12h of exposure to IFN-α and IFN-β. Real-time polymerase chain 
reaction was performed for IFNR1 and IFNR2 as described in methods. Data are 
expressed relative to their respective 18s rRNA expression and are means ± SEM of three 
experiments.  
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4.2 dsDNA trigger IFN-stimulated genes (ISGs) in glomerular epithelial cells  
 During viral infection, cells secrete a large amount of IFNs that act in a 
paracrine and in an autocrine manner. Synthetic nucleic acids together with viral 
nucleic acids are the most potent inducers of type I IFNs. In order to study the 
potential of viral infections to activate the IFN induced antiviral state on 
glomerular epithelial cells, podocytes and PECs from human and mouse origin 
were stimulated with synthetic dsDNA (poly-dAdT) complexes with 
lipofectamine to mimic viral infection. After 12h the stimulation was stopped and 
cellular mRNA collected. RT-PCR analysis showed significant up-regulation of 
IFN stimulated genes (ISGs) in glomerular epithelial cells upon (poly-dAdT) 
stimulation compared to the controls for both species (Figure 10). The induction 
of ISGs is a mechanism through which type I IFNs establish the cellular antiviral 
state on target cells. MX proteins belong to the class of dynamin-like large 
guanosine triphosphateses (GTPases), and they have an antiviral activity against a 
wide range of RNA viruses. These proteins are major components of the antiviral 
state induced by IFN. [212]. IFT1 and IFIT3 genes belong to the ISG56 family 
genes. Under normal conditions these genes are silent and their transcription is 
strongly induced by type I IFNs stimulation and viral infection [212]. CXCL10, 
also known as IP-10, is an IFN induced chemokine involved in the recruitment of 
immune cells. [213]. Altogether, dsDNA stimulation significantly triggers 
expression of multiple ISGs in podocytes and PECs of both species. 
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Figure 10. IFN type I signature in human and mouse parietal glomerular epithelial 
cells and podocytes. Human (A, C) and murine (B, D) glomerular epithelial cell mRNA 
was isolated after 12h of exposure to synthetic double strand DNA (poly-dAdT) 
complexes with lipofectamine. Real-time polymerase chain reaction was performed for 
the indicated ISG genes as described in results methods. Data are expressed relative to 
their respective 18s rRNA expression and are means ± SEM of three experiments and are 
means ± SEM of three independent experiments *P < 0.05 versus control; **P < 0.01 
versus control. 
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4.3 dsDNA stimulation modulate CD133+/CD24+ PECs properties  
 In contrast to glomerular visceral epithelial cells, which do not proliferate 
in-vitro or in vivo, PECs have the ability to enter and successfully complete the 
cell cycle. Human CD133+/CD24+ renal progenitor cells within the PEC layer at 
the inner aspect of the Bowman`s capsule have been postulated to be involved in 
glomerular repair processes. Together with their ability to proliferate, they have 
been shown to have the capacity to differentiate towards podocytes in culture and 
to restore podocyte loss in-vivo [117, 206]. Many kidney diseases are directly or 
indirectly related to viral infections, but how and to which extend viral infections 
can affect glomerular regeneration is still unknown. In order to replace podocyte 
loss, human CD133+/CD24+ PECs need to increase their number to start the 
differentiation process. To address the question how viral infections can affect 
this process, human CD133+/CD24+ PECs were stimulated with dsDNA 
complexes and MTT proliferation assay was assessed. The cells were stimulated 
with three different concentrations of synthetic dsDNA complexes and the assay 
was carried out for three different time points. (Figure 11) Already after 24h of 
stimulation, dsDNA complexes down regulated human CD133+/CD24+PECs 
proliferation in dose dependent manner. The arrest of cell proliferation has been 
observed to be dose dependent. 
 Furthermore, the potential of renal progenitors to differentiate into 
podocytes was tested. This was achieved by exposing parietal epithelial renal 
progenitors to the appropriate differentiation medium (VRADD) in presence of 
dsDNA complexes or lipofectamine alone for 48h. At the end of the experiment, 
quantification of nephrin mRNA expression was used to evaluate the 
differentiation of renal progenitor towards podocytes. (Figure 11)  Renal 
progenitors were cultured in their normal medium for 48h as a control for nephrin 
expression. dsDNA complexes significantly reduced the capacity of podocyte 
progenitors to induce nephrin mRNA expression, indicating the negative role of 
viral infections and their mediators during the differentiation process. These data 
show two critical effects of IFNs and dsDNA on glomerular epithelial progenitor 
cells: dsDNA suppresses glomerular progenitor proliferation and inhibits their 
differentiation into mature podocytes. 
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Figure 11. dsDNA modulate CD133/CD24+ PECs  proliferation and differentation 
towards podocytes. (A-C) Human CD133/CD24+ PECs were cultured with synthetic ds 
DNA (poly-dAdT) complexes with lipofectamine (CL) for 24h (A), 48h (B) and 72h (C). 
Cells proliferation was evualated by MTT assay as described in the methods. Data are 
means ± SEM of three experiments, each analyzed in quadruplicate . *P < 0.05 versus 
CL; **P < 0.01 versus CL; ***P < 0.001 CL. (D) Human CD133/CD24+ PECs were 
cultured in the VRADD medium +/- ds DNA (poly-dAdT) complexes with lipofectamine 
(CL) at the concentration of 1,5µg/ml (v/v) for 48h and nephrin mRNA expression was 
quantified by Taq-Man RT-PCR as described in the methods. As control, renal 
progenitors were cultured for 48h in normal growth medium +/- ds DNA (poly-dAdT) 
complexes with lipofectamine (CL) at the concentration of 1,5µg/ml (v/v). Data are 
expressed relative to their respective 18s rRNA expression and are means ± SEM of three 
independent experiments *P < 0.05 versus CL; **P < 0.01 versus CL; ***P < 0.001 
versus CL.  
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4.4 IFN-α and IFN-β trigger the expression of multiple ISGs in podocytes and 
PECs 
 To verify the potential of IFNs to activate the cellular antiviral state on 
glomerular epithelial cells, podocytes and PECs from human and mouse origin 
were exposed to IFN-α and IFN-β respectively. After 12h the stimulation was 
stopped and the cells collected. RT-PCR analysis showed significant up-
regulation of ISGs in glomerular epithelial cells upon type I IFN stimulation 
compared to the controls. Therefore, it can be concluded that the induction of 
ISGs is the mechanism by which these cytokines establish the cellular antiviral 
state on the target cells. In podocytes from human and mouse origin, IFN beta 
stimulation resulted in a higher up-regulation of ISGs compared to IFN alpha, 
indicating a major susceptibility of podocytes to IFN beta stimulation. Altogether, 
both IFN-α and IFN-β induce significantly multiple ISGs in podocytes and PECs 
of both species (Figure 12). Thus, the antiviral cytokines IFN-α and IFN-β 
activate both podocytes and PECs. 
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Figure 12. IFN type I signature in human and mouse PECs and podocytes. Human 
(A, C) and murine (B, D) glomerular epithelial cell mRNA was isolated after 12h of 
exposure to IFN α/β  (1000U/ml). Real-time polymerase chain reaction was performed 
for the indicated ISG genes as described in results methods. Data are expressed relative 
to their respective 18s rRNA expression and are means ± SEM of three experiments and 
are means ± SEM of three independent experiments  *P < 0.05 versus control  **P < 0.01 
versus control; ***P < 0.001 versus control 
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4.5 Only IFN-β increases monolayer permeability of podocyte  
 Based on the consistent activation of podocytes by both IFN-α and IFN-β, 
their effect on podocyte permeability, used as a biomarker of their glomerular 
filtration barrier function, was evaluated. Murine podocytes were used to perform 
electrical cell impedance assay (ECIS) to evaluate changes in podocyte resistance 
upon IFN stimulation and to quantify alterations in the barrier function of cell 
monolayers in-vitro [211, 214]. Cellular resistance was significantly decreased in 
response of IFN-β as early as 5 min of stimulation (Figure 10 B) in murine 
podocytes. In human podocytes IFN-β affected cellular resistance in a similar 
manner but not until 2h of stimulation (Figure 10 A). In contrast, IFN-α 
stimulation in both species did not affect podocyte monolayer resistance as 
compared to the control. Changes in podocyte activation can be transient or 
persistent and may eventually lead to podocyte detachment and/or death [95]. In 
order to address this question podocytes were exposed to IFN-β for 24h and cell 
death was analysed by flow cytometry. Flow cytometer analysis of podocyte 
culture supernatant showed an increased number of PI+ cells upon IFN-β 
stimulation as compared to control (31,6% vs. 16.4% of detached cells) (Figure 
13). This suggests that IFN-β, but not IFN-α, modulates the glomerular filtration 
barrier by affecting stability of the podocyte monolayer architecture.  
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Figure 13. IFN-β increases podocyte monolayer permeability by causing podocyte 
detachment. (A) Human and  (B) mouse podocytes were seeded into ECIS culture ware 
and grown to confluence. Monolayer resistance was analyzed for 30 min or 12 h, 
respectively. Data are expressed as normalized resistance ± SEM for three independent 
experiments.  (C-D) An equal number of human podocytes were exposed to medium 
(black) or IFN-β (open/white). After 24 h propidium iodide (PI) flow cytometry of the 
cell culture supernatant of PI positive detached cells was performed. Data are means ± 
SEM of three experiments. *P < 0.05 versus control 
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4.6 IFN-β affects podocyte viability by promoting cell death 
 Increased podocyte permeability is associated with cytoskeleton 
modification and loss of podocyte architecture complexity [13]. Modification of 
the cellular shape can lead to cellular damage and death. Inflammatory cytokines 
have been reported to trigger in-vivo and in-vitro podocyte damage and 
progressive loss of kidney function. Yet, how the antiviral type I IFNs affect 
podocyte viability is still not clear [215, 216]. Based on the permeability data, 
only IFN-β  modulated podocyte permeability by increasing the detachment. In 
order to understand if this increase of podocyte detachment was correlated with 
podocyte death, human and murine podocytes were exposed to IFN-β  for 24h and 
analysed by flow cytometry. IFN-β exposure significantly increased the numbers 
of PI+ podocytes from both species while the effect on annexin V staining was 
stronger in mouse podocytes (Figure 14). Type I IFNs exert potent pro-apoptotic 
effects on several cell types, by inducing pro apoptotic molecules [217, 218]. To 
verify the effects of IFN-β on glomerular podocytes , pro-apoptotic gene 
expression analysis was performed. RT-PCR analysis showed a significantly 
increased expression of several pro-apoptotic genes, such as PUMA, BAK, BAX, 
and BID, compared to control (Figure 14). 
Altogether, IFN-β modulates podocyte viability in-vitro by triggering detachment, 
leading to apoptosis and/or necrosis. 
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Figure 14. IFN-β  modulate podocyte viability by promoting death. Human (A) and 
mouse (B) podocytes were cultured +/- IFN-β (5000U/ml) for 24h and propidium iodide 
(PI) and annexin V flow cytometry was assessed to quantifies their viability. Podocyte 
mRNA from both the species (C: human, D: mouse) was isolated after 12h of exposure to 
IFN-β (5000U/ml) and real-time polymerase chain reaction was performed for the 
indicated pro apoptotic genes as described in the Methods. Data are expressed relative to 
their respective 18s rRNA expression and are means ± SEM of three experiments. *P < 
0.05 versus control ; **P < 0.01 versus control; ***P < 0.001 versus control 
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4.7 IFN-α but not IFN-β modulate parietal epithelial cell proliferation  
 In contrast to the highly differentiated podocytes, PECs easily proliferate 
in culture or in-vivo, for example when GBM rupture exposes them to serum. 
This drives PEC overgrowth in the Bowman`s space and ultimately leads to 
glomerular crescent formation [24]. During viral infection, local and systemic 
type I IFNs increased affecting homeostasis of target cells. PECs express both 
types of IFN receptor chains, but the pathogenic effects of these cytokines on 
PECs homeostasis is not known. To start out, how IFN-α and-β affected PECs 
proliferation, contributing or preventing aberrant parietal epithelial cells 
proliferation was investigated. To evaluate PEC viability and growth upon IFN-α 
and IFN-β stimulation, MTT assays were assessed. After 72h of stimulation, IFN-
α but not IFN-β, significantly reduced the viability of both human and murine 
PECs (Figure 15). Reduced PEC viability correlated with IFN-α exposure and can 
be associated with induction of cellular death or cell cycle modulation. To 
evaluate if this decrease of proliferation was due to the ability of type I IFNs to 
trigger cell death, murine and human PECs were exposed to IFN-α and IFN-β for 
24h, and PI/annexin V flow cytometry analysis was performed. Flow cytometry 
analysis revealed that the reduced viability of PECs upon IFN-α and IFN-β 
stimulation did not correlate with an increase in cellular death. (Figure 15) 
Altogether, this suggests that IFN-α, but not IFN-β, modulates PEC proliferation 
without triggering cell death. 
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Figure 15. IFN-α   affects PECs proliferation. Human and murine renal PEC were 
cultured with IFNα/β (5000U/ml) for 24h and cells proliferation was assessed (A, C). 
Data are means ± SEM of three experiments, each analysed in quadruplicate. *P < 0.05 
versus. In similar experiment human and murine PEC stimulated for 24h with or without 
IFNα/β (5000U/ml) were stained with anti-annexin V and PI and analyzed by flow 
cytometry (B, D). The figure displays one representative of several experiments.  
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4.8 IFN-α modulate PECs cell cycle by p21 up-regulation  
 Cell cycle arrest has been reported to be part of the antiviral defense 
mechanism activated by the release of type I IFN cytokines to limit viral 
replication in the host [161, 219]. To investigate whether IFNα affects PECs 
viability by modulating cell cycle progression, human and mouse PECs were 
cultured +/- IFNα/β,  and cell cycle analysis by PI staining was performed. Flow 
cytometry analysis showed a decrease of cell numbers in the S-phase (DNA 
replication phase) in the sample exposed to IFN-α compared to the control. This 
was not observed in samples exposed to IFN-β (Figure 16). The cell cycle is 
strictly regulated by expression of cyclins and cyclin-dependent Kinases (CKDs). 
Two distinct classes of these cell cycle regulators, inhibitors and activators 
orchestrate the entry or the arrest into the next cell cycle phase. To investigate 
through which mechanism IFN-α promotes cell cycle arrest in glomerular PECs, 
cells from humans and mice were cultured +/- IFNα/β for 24h, and cellular 
protein was harvested. Western-blot analysis for expression of the cyclin-
dependent kinase inhibitor-1 p21, which is associated with arrest of the cell cycle 
in G1 phase, was performed (Figure 16). PECs exposed to IFNα, but not to IFN-
β , showed an increased expression of p21 compared to the control. Thus, all 
together this shows that in parietal epithelial cells, IFN-α inhibit cell cycle 
progression from G1 phase to S phase, by p21 up-regulation. 
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Figure 16. IFN-α  arrest PEC growth affecting their cell cycle. Human (A-B) and 
mouse (D-E) were culture +/- IFNα/β  5000U/ml) for 24 h and cell cycle analysis by PI 
staining was performed as described in the methods. Data are means ± SEM of three 
experiments, each analyzed in duplicate.*P < 0.05 versus control (S-phase) ; **P < 0.01 
control (S-phase) ; ***P < 0.001 control (S-phase). (C,F) In similar experiment cellular 
lysates from human and murine PECs were analyzed by western blot for the expression of 
p21. β-Actin staining is shown as loading control. The figure displays one representative 
of several blots from three independent experiments 
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4.9 IFN-α modulate PEC migration but both IFN I suppress progenitor 
differentiation  
 Human CD133+/CD24+ renal progenitor cells within the PEC layer at the 
inner aspect of the Bowman`s capsule have the capacity to differentiate to 
podocytes in culture and may restore podocyte loss in-vivo [117, 206]. This 
concept of progenitor PEC-derived podocytes is supported by lineage tracing 
experiments in transgenic mice during renal development and growth [120]. Vice 
versa, persistent proteinuria and glomerular scaring may imply that the activation 
of quiescent PEC progenitors, their co-ordinated proliferation and migration to 
the glomerular tuft, and finally, their differentiation into mature podocytes is 
significantly impaired and podocyte loss rather results in focal scar formation 
[38]. In this scenario, intra and extra renal infections might interfere with 
glomerular regeneration by realising inflammatory antiviral cytokines, such as 
type I IFNs.  To investigate if types I IFNs induce all necessary steps for 
podocyte regeneration from their PEC progenitors, the impact of IFN-α and IFN-
β on renal human CD133+/CD24+PECs was evaluated. Wound healing assays on 
human renal progenitor monolayers and murine PECs was performed, which 
involve the activation and migration of surviving cells to close the wound, 
consistent with its negative regulation of migration. Exposure to IFN-α, but not to 
IFN-β, significantly reduced the migratory capacity of these cells to close the 
wound (Figure 17). Furthermore, the potential of renal progenitors to differentiate 
in-vitro towards podocytes was tested. This was achieved by exposing parietal 
epithelial renal progenitors to the appropriate differentiation medium (VRADD) 
in presence of type I IFNs for 48h.  At the end of the experiment, quantification 
of nephrin mRNA expression was used to evaluate the differentiation of renal 
progenitors towards podocytes. IFN-α and IFN-β both significantly reduced the 
capacity of podocyte progenitors to induce nephrin mRNA expression, indicating 
the role of these inflammatory cytokines during the differentiation process 
(Figure 17). The effect was more pronounced for IFN-β, probably because IFN-β 
also killed mature podocytes as observed before. These data show two critical 
effects of the IFN subtypes on glomerular epithelial cells. First, IFN-α 
specifically suppresses PEC migration; second, both IFN-α and IFN-β inhibit 
  
 75 
renal progenitor differentiation into mature podocytes, which then adds on to 
podocyte loss by IFN-β-induced podocyte death.  
 
 
Figure 17. IFNα /β  modulate PEC migration and podocyte progenitor 
differentiation  
Cell migration assay +/- IFN-α/-β (5000U/ml) was performed with human (A) and 
murine (B) PECs using culture inserts as described in methods. Data shown represents 
mean wound size at the end of the experiment. (Data are expressed as means ± SEM of 
three independent experiments. **P < 0.01 versus control; ***P < 0.001 versus control. 
(C) Human renal progenitors were cultured in the VRADD medium +/- h 
IFNα/β (5000U/ml) for 48h and nephrin quantification by Taq-Man RT-PCR was 
performed as described in the Methods. As control, renal progenitors were cultured for 
48h in normal growth medium as described in the Methods. Data are expressed relative to 
their respective 18s rRNA expression and are means ± SEM of three independent 
experiments *P < 0.05 versus control; **P < 0.01 versus control; ***P < 0.001 versus 
control.  
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4.10 IFN-α and IFN-β aggravate glomerulosclerosis in adriamicyn-induced 
nephropathy in SCID mice  
 Extra renal and intra renal infections can aggravate kidney damage by 
exposing glomerular cells to large amounts of type I IFNs. To test the functional 
significance of type I IFN in the pathogenesis of glomerular damage, recombinant 
IFN-α or IFN-β were injected into mice with adriamycin-induced FSGS [67]. To 
focus on the intrarenal effects of the IFNs, all experiments were performed in 
SCID mice lacking adaptive immunity. This allowed for exclusion of secondary 
effects due to immunomodulatory properties of type I IFNs. All animals received 
adriamycin at the dose of 6,5 mg/kg by retro-orbital injection and three groups 
were assessed. For seven days, the animals received injections of recombinant 
IFN-α or IFN-β or saline daily. At day 7 the animals were sacrificed and organs 
collected for retrospective analysis. Injections with either recombinant IFN-α or 
IFN-β significantly aggravated proteinuria and focal segmental tuft adhesions and 
sclerosis by day 7 of mice with adriamycin nephropathy (Figure18). However, the 
effect of IFN-β was much more prominent than that of IFN-α.  Taken together, 
IFN-α and IFN-β both have the potential to aggravate proteinuria and glomerular 
pathology in SCID mice with FSGS. 
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Figure 18. IFN-α  and IFN-β  aggravate adriamycin-induced nephropathy in SCID 
mice.  (Α) Albumin/creatinine ratios were measured in mice were measured in mice 
injected with adriamycin compared to adriamicyn+IFN-α (1000U) and adriamicyn+IFN-
β (1000U) injected mice after 7 days. Data from one representative of three independent 
experiments in shown. Data are expressed as means ± SEM. (n=6 mice for each 
experiment and for each group of treatment). *P < 0.05 versus adriamycin; ***P < 0.001 
versus adriamycin. (B) Representative images from periodic acid shiff stains of all groups 
are shown at original magnification of x 400 
 
 
4.11 IFN-α and IFN-β trigger expression of multiple ISGs in-vivo 
 Consistent with the previous in-vitro data, IFN-α and IFN-β showed the 
ability to activate and induce the expression of ISGs in glomerular cells in-vitro. 
To extend this finding in-vivo, kidney samples from SCID mice with FSGS, were 
analyzed. Kidney mRNA from mice injected with both IFNs was extracted and 
RT-PCR analysis for ISG was performed.  Both groups treated with IFN-α and 
IFN-β showed increased intrarenal mRNA expression of ISGs (MX1, IFIT1, 
IFIT3, and CXCL10), indicating the ability of IFNs to activate glomerular cells, 
both in-vitro and in-vivo (Figure 19).  
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Figure 19. Both IFN-α  and IFN-β  induced intrarenal expression of ISGs and 
inflammatory markers. Total kidney mRNA was extracted from mice injected with 
adriamycin or with adriamycin +IFNα/β (1000U) after 7 days of treatment. Real-time 
polymerase chain reaction was performed for the targeted ISG genes as described in the 
Methods. Data are expressed relative to their respective 18S rRNA expression and are 
means ± SEM of three experiments (n=6 mice for each experiment and for each group of 
treatment) *P < 0.05 versus adriamycin; **P < 0.01 versus adriamycin; ***P < 0.001 
versus adriamycin 
 
 
4.12 IFN-α and IFN-β treatment increase glomerular inflammation  
 Classically, type I IFNs specifically target innate and adaptive immune 
responses.  In vivo, they promote natural killer cell cytotoxicity, as well as they 
enhance macrophage maturation, and inducible nitric oxide synthase production. 
Both IFNs showed the ability to regulate the expression of multiple 
proinflammatory cytokines and chemokines, in immune cells and as well as in 
non-immune cells. SCID mice lack adaptive immune cells, but not innate immune 
cells like macrophages. To investigate to which extent IFN injections orchestrate 
the innate immune response in the pathogenesis of adriamycin-induced FSGS, 
glomerular macrophages were quantified by confocal microscopy. Kidney 
sections from the mice were stained for CD68, used as macrophage marker, and 
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Claudin I (CLDN1) to stain PECs lying of the Bowman’s capsule. Increased 
numbers of glomerular CD68+ macrophages for both IFNs has been detected, 
confirming the role of IFNs in modulating innate immune cells (Figure 20) In 
accordance, mRNA gene expression analysis was performed to profile 
proinflammatory cytokines (IL-6, TNF-α) and chemokines (CXCL9, CXCL11) 
expression in the kidney. Samples from both groups treated with type I IFNs 
showed an increased level of proinflammatory cytokine expression compared with 
the vehicle group (Figure 20). Thus, IFN-α and IFN-β both have the potential to 
direct innate immunity and contribute to tissue inflammation by increasing 
glomerular macrophage numbers and triggering intrarenal proinflammatory 
secretion in-vivo. This type of immune response can aggravate glomerular 
damage in SCID mice with FSGS. 
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Figure 20. IFNs type I activate intrinsic renal cells and macrophages in vivo. (A) 
Quantification of CD68+ macrophages/glomerulus after 7 days of injury. Data are 
expressed as means ± SEM and are representative of three independent experiments (n=6 
mice for each experiment and for each group of treatment). *P < 0.05 versus adriamycin; 
**P < 0.01 versus adriamycin;***P < 0.001 versus adriamycin. (B) Representative 
picture of double-label immunofluorescence for Claudin-1 (CLDN1) (red) and CD68 
macrophages (green). (C) Total kidney mRNA was extracted from mice injected with 
adriamycin or with adriamycin +IFNα/β (1000U) after 7 days of treatment. RT-PCR 
reaction was performed for the pro-inflammatory markers as described in the methods. 
Data are expressed relative to their respective 18S rRNA expression and are means ± 
SEM of three experiments *P < 0.05 versus adriamycin; **P < 0.01 versus adriamycin;  
 
 
4.13 IFN-α and IFN-β have distinct effects on podocytes in-vivo 
 Since in-vitro studies showed that IFN-α and IFN-β elicit distinct and 
differential effects on podocytes in-vitro, we investigated this possibility in-vivo. 
Podocyte injury is the culprit in the pathogenesis of glomerular damage leading to 
development of proteinuria.  According with the in-vitro data, IFN-β modulates 
the glomerular filtration barrier by triggering podocyte detachment/death in-vitro. 
To question the impact of IFN injection on glomerular podocyte numbers in 
adriamycin-induced FSGS, histological analysis of the kidney from all the groups 
was assessed. Kidney samples were stained for two different podocyte markers 
nephrin (NPHS1) and WT-1, and confocal analysis was performed. Consistent 
with our in-vitro data, IFN-β injections reduced the numbers of NPHS1+/WT-1+ 
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podocytes in SCID mice with adriamycin nephropathy as compared to the vehicle 
control group (Figure 21). By contrast, impact of IFN-α injections on podocyte 
numbers was less dramatic compared to the group injected with IFN-β. 
Prove of podocyte apoptosis are really poor in the literature, and a new concept 
regarding podocytes death is emerging How do podocytes die? It was believed 
that they die by apoptosis. But, there is a little experimental proof to this concept 
in the current literature. However, recently there are few reports which suggest 
catastrophic mitosis as a new mechanism of podocyte death in-vivo[104]. 
Podocyte are terminally differentiated epithelial cells, which have lost the 
capacity to divide. During inflammation, cytokines and other mediators might 
signal podocytes to re-entry the cell cycle to compensate the loss of neighbour 
cells. Frequently, this process leads to podocyte death by a mechanism called 
catastrophic mitosis. Podocytes can neither complete cytokinesis nor maintain 
their function as aneuploidy cells [105, 220, 221]. 
To characterize if IFN-β injection affects podocyte loss by inducing catastrophic 
mitosis, double immune-fluorescent for the podocyte marker podocin (NPHS2) 
and for histone H3 phosphorylated at serine 10 (P-H3) was performed in the 
kidney sections (Figure 21C, 21D). P-H3 marks the prophase of nuclear division 
in cells that are about to complete mitosis. Podocyte P-H3 staining was absent in 
healthy mouse kidneys. Control SCID mice with adriamycin nephropathy showed 
a small number of P-H3 positive podocytes, however, the number of P-H3 
positive podocytes per glomerulus was increased in mice that had received IFN-β 
injections. Mice treated with IFN-α did not show any change in the number of P-
H3 positive podocytes, while mice treated with IFN-β showed significantly less P-
H3 positive podocytes compared to the control. This suggests that IFN-β affect 
podocyte viability in-vivo by triggering podocyte through catastrophic mitosis. 
 
  
 82 
 
 
 
Figure 21. IFN-β  aggravates podocyte loss in FSGS. (A) Quantification of number of 
podocyte (NPHS1+WT-1+)/glomerulus after 7 days of treatment. Data are expressed as 
means ± SEM and they are representative of three independent experiment. (n=6 mice for 
each experiment and for each group of treatment).; **P < 0.01 versus adriamycin;. (B) 
Representative pictures of double-label immunofluorescence for WT-1 (red) and NPHS1 
(green). (C) Quantification of number of mitotic podocyte (NPHS2+P-H3+)/glomerulus 
after 7 days of treatment. Data are expressed as means ± SEM and they are representative 
of three independent experiment. (n=6 mice for each experiment and for each group of 
treatment).; *P < 0.05 versus adriamycin;. (D) Representative picture of double-label 
immunofluorescence for NPHS2 (red) and P-H3 (green).  
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4.14 IFN-α and IFN-β have distinct effects on PEC mitosis in-vivo 
 The in-vitro results imply that predominantly IFN-α, not IFN-β, affects 
PECs, for example by inducing PEC senescence. To study the impact of IFN 
injection on proliferating PECs in adriamycin-induced FSGS, histological analysis 
of the kidney from all the groups was assessed. Kidney sections were stained for 
the PEC marker CLDN1 and for P-H3, used as marker for mitotic cells (Figure 
22). CLDN1/P-H3 positive PECs were absent in healthy mouse kidneys; by 
contrast, SCID mice with adriamycin nephropathy displayed P-H3 positive PECs, 
in accordance with their role in glomerular regeneration. However, their numbers 
were significantly decreased upon IFN-α injections while IFN-β injections had no 
such effect (Figure 22). Thus, although IFN-α and IFN-β both aggravate 
adriamycin-induced proteinuria and FSGS, both have differential effects on 
glomerular epithelial cells, podocytes and PECs, which are consistent with the in-
vitro results. 
 
Figure 22. IFN-α  affect PEC proliferation in-vivo. (A) Quantification of number of 
proliferating PEC (P-H3+CLDN1+)/glomerulus after 7 days of treatment. Data are 
expressed as means ± SEM and they are representative of three independent experiment. 
(n=6 mice for each experiment and for each group of treatment).; **P < 0.01 versus 
adriamycin;. (B) Representative pictures of double-label immunofluorescence for CLDN1 
(red) and P-H3 (green).  
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4.15 IFN-α and IFN-β aggravate proteinuria and podocyte damage in 
adriamycin-induced nephropathy in Balb/c mice 
 Adriamycin-induced nephropathy is a model that, to a certain extent, 
induces a significant component of extra renal adaptive immunity. In order to test 
the functional significance of Type I IFN in the pathogenesis of FSGS, injection 
of either recombinant IFN-α or IFN-β into immunocompetent Balb/c treated with 
adriamycin was performed. All animals received adriamycin at the dose of 11,5 
mg/kg by retro-orbital injection. Study mice were divided into three groups: 
animals received injections of either recombinant IFN-α or IFN-β or saline daily 
for seven days. After day seven the animals were sacrificed and organs collected 
for retrospective analysis. Injections with either recombinant IFN-α or IFN-β 
aggravated proteinuria by day 7, compared with the control (Figure 23). To 
investigate how IFN injection affects glomerular podocyte homeostasis, confocal 
analysis of podocytes was performed. Kidney sections from all groups were 
stained for the podocyte markers NPHS1 and WT-1 (Figure 23). Samples from 
both groups treated with type I IFNs showed a slightly decreased number of 
NPHS1+/WT-1+ podocytes compared with the vehicle group. No significant 
difference has been observed between the two groups, as it was observed in SCID 
mice. These data indicate that both IFNs have the ability to aggravate glomerular 
injury in immunocompetent model, with a different extent when compared to non-
immunocompetent model 
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Figure 23. IFN-α  and IFN-β  aggravate adriamycin-induced nephropathy in Balb/c 
mice.  (Α)   Albumin/creatinine ratios were measured in mice were measured in mice 
injected with adriamycin compared to adriamicyn+IFN-α (1000U) and adriamicyn+IFN-
β (1000U) injected mice after 7 days. Data from one representative of three independent 
experiments in shown. Data are expressed as means ± SEM. (n=6 mice for each 
experiment and for each group of treatment). ***P < 0.001 versus adriamycin. (B) 
Representative pictures of double-label immunofluorescence for WT-1 (red) and 
NPHS1(green). 
 
 
4.16 IFN-α and IFN-β injection modulate glomerular infiltrated immune cells  
 Podocyte damage and loss is the culprit in the pathogenesis of FSGS. 
However, this model involves intra and extra renal adaptive immune responses 
that might be modulated, by systemic IFN-α/β injections. Classically, type I IFNs 
specifically target innate and adaptive immune responses in vivo, activating 
immune cells and promoting their maturation. This mechanism could potentially 
aggravate renal disease. To investigate to which extent IFN injections orchestrate 
intra renal innate and adaptive immune response in adriamycin-induced FSGS, 
immunohistochemical analysis of immune cells was performed. Kidney sections 
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from animals sacrificed after 7 days of treatment were stained for CD3, a 
lymphocyte marker and for Mac2, a macrophage marker. It was observed that the 
glomerular CD3 lymphocytes remain unchanged (Figure 24) while the numbers of 
glomerular mac-2 positive macrophages were increased after the treatment of both 
IFN-α and-β, compared to the control (Figure 25). In summary, these data showed 
that both IFNs increased glomerular macrophage infiltrate, a mechanism that 
contributes to aggravate glomerular damage in adriamycin-induced FSGS in 
Balb/c mice. 
 
 
 
 
Figure 24. IFN-α  and IFN-β  do not increase intra glomerular lymphocyte infiltrate. 
(A) Quantification of number of lymphocyte (CD3+)/glomerulus after 7 days of IFNα/β 
treatment. Data are expressed as means ± SEM and they are representative of three 
independent experiment. (n=6 mice for each experiment and for each group of treatment). 
(B) Representative pictures of CD3 immune staining (black). 
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Figure 25. IFN-α  and IFN-β  modulates glomerular macrophages. (A) Quantification 
of number of macrophages (Mac2+)/glomerulus after 7 days of IFNα/β treatment. Data 
are expressed as means ± SEM and they are representative of three independent 
experiment. (n=6 mice for each experiment and for each group of treatment).; *P < 0.05 
versus adriamycin;**P < 0.01 versus adriamycin;. (B) Representative pictures of Mac2 
immune staining (black). 
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5. Discussion 
 We have hypothesized that during viral glomerulonephritis, e.g HIVAN, 
viral replication inside podocytes and PECs would trigger IFN type I-dependent 
antiviral responses, process that contributes to glomerular damage. IFN-α and 
IFN-β coordinate antiviral immunity, which involves the activation of innate and 
adaptive immunity in addition to numerous other biological effects that support 
antiviral host defense [204, 222]. Even though viral nephropathies represent an 
important entity in clinical nephropathy little is known about the biological effects 
of these enigmatic cytokines inside the kidney. During viral infection, viral 
nucleic acid enters into the cells and is recognized by innate immune pathways 
[223, 224]. Intracellular nucleic acid recognition mediated by TLRs or RIG-I 
helicases, leads to activation of interferon regulatory factors (IRFs), resulting in 
type I IFNs secretion. These cytokines mediate induction of "cellular antiviral 
state" that restricts further viral spread [180]. Activation of "cellular antiviral 
state" is characterized by the up-regulation of ISGs, normally silent, that are 
involved in the inhibition of both viral replication and cellular proliferation. These 
genes, like IFIT family genes or MX1, are strictly regulated by type I IFNs [222, 
225]. It has been reported that glomerular epithelial cells can be infected by 
certain viruses in-vivo, for example HIV and parvovirus B19, leading to viral 
nephropathy [132, 226-229]. Podocytes, even though they lack the classical HIV 
receptors, are susceptible to infection by this virus, resulting in the development 
of collapsing FSGS. HIV-1 is a single-stranded positive- sense enveloped RNA 
virus, which has a strong tropism for lymphoid tissue. However, it has been 
reported to infect many different cell types.  PECs are not susceptible to HIV 
infection during HIV mediated collapsing FSGS, however, they have been shown 
to be infected by PVB19, leading to nephropathy. 
 In this thesis it has been shown that podocytes and PECs from mouse and 
human origin can be infected and activated by synthetic nucleic acid. Infection 
with synthetic nucleic acid leads to activation of "the type I IFN dependent 
antiviral state" in both cell types, a mechanism which is induced by the up-
regulation of ISGs. It is likely to assume that up-regulation of ISGs upon viral 
infection is a mechanism of glomerular epithelial cells to protect themselves from 
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infection and virus propagation. The ISGs found up-regulated in both cell types 
after synthetic nucleic acid infection correspond to the typical gene expression 
profile regulated by type I IFNs, also known as " type I IFN signature". 
 To further investigate how the activation of "cellular antiviral state", 
regulated by type I IFNs, might modulate glomerular epithelial cell homeostasis 
and turnover, the impact of nucleic acid infection on human CD133+/CD24+ 
PECs was studied. This particular subpopulation of PEC layer has shown to be 
involved in glomerular regeneration by restoring podocyte loss through 
differentiation processes similar to that of adult stem cell progenitors [16, 25, 38, 
84, 117]. In accordance with the activation of the cellular antiviral state upon 
synthetic nucleic acid activation, the present study demonstrates that viral 
infections modulate CD133+/CD24+PECs homeostasis by arresting cell 
proliferation.  
 In order to replace podocyte loss, human CD133/CD24+ PECs need to 
increase their number to start the differentiation process. Furthermore, the present 
work has demonstrated that infection with synthetic nucleic acid inhibits 
CD133+/CD24+PECs differentiation towards mature podocytes. These effects, 
modulated by dsDNA induced IFNs, might contribute to the development of 
glomerular lesion during viral nephropathy. In order to confirm the hypothesis 
that all these results can be derived from induction of type I IFNs upon viral 
infection, the direct effects of IFN-α and IFN-β on PECs and podocytes from 
human and mouse origin were tested. The data obtained demonstrate the ability of 
both IFNs to activated the cellular antiviral state by up-regulation of ISGs, with a 
prominent effect of IFN-β on podocytes from both the species, indicating a major 
susceptibility of these cells by IFN-β.  
 Despite the fact that IFNAR deficiency has been reported to protect mice 
from glomerulonephritis [199, 204, 205], Satchell et al. reported anti-proteinuric 
effects of IFN-β in glomerular diseases of immunocompetent rodents and 
Schwarting et al. reported protective effects of IFN-β on lupus nephritis of 
MRLlpr mice [201] [200]. In order to interpret these discrepant results, the 
underlying mechanisms of type I IFNs affecting podocyte and PEC homeostasis 
was studied in-vitro. Based on the observation that human and mouse podocytes 
exposed to IFN-b and IFN-a strongly up-regulate ISGs, the effects of both IFNs 
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on podocyte permeability were studied. Hence, ISG levels were used as a 
biomarker for glomerular filtration barrier function. 
In contrast to previous reports in literature, this work demonstrates that IFN-β, but 
not IFN-α affects the glomerular filtration barrier in-vitro. Within few min of 
IFN-β exposure cultured podocytes changed their shape, possibly by retracting 
cytoplasmic extensions. This altered ECIS bio impedance measurements, a 
functional parameter of podocyte monolayer permeability and cellular shape 
[211]. Satchell et al. had used the same bio impedance device and reported 
opposite results upon IFN-β stimulation [201] . Their studies were performed with 
immature and proliferating glomerular epithelial cells of human origin, which 
does not allow predictions on the filtration barrier created by terminally 
differentiated podocytes that we studied.  In this thesis, decrease in podocyte 
permeability driven by IFN-β, was observed in podocytes from murine origin 
after few min. In contrast, the same effect on human podocytes was observed after 
6 h. Murine and human podocytes show the same response but at different time 
points, probably due to intrinsic differences between the two species analyzed. 
Decreased cellular permeability was not detected in podocytes from human and 
murine origin exposed to IFN-α, indicating distinct effects of type I IFNs on 
glomerular podocytes.  
 What are the consequences of the dramatically decreased podocyte 
permeability, driven by IFN-β? The bio-impedance data gathered during this 
thesis has shown that treatment with IFN-β engenders podocyte detachment, 
leading to cellular death as assessed by annexin V/PI flow cytometry. Similarly, 
gene expression profiles confirm this new finding by showing a prominent up-
regulation of apoptotic genes in podocytes upon IFN-β exposure. How does IFN-β 
kill podocytes in-vivo? 
 The in-vivo results support in-vitro findings, since IFN-β-treated SCID 
mice suffered from higher podocyte loss and proteinuria during adriamycin 
nephropathy compared to the IFN-α or vehicle treatment. Increased podocyte 
mitotic activity was detected in IFN-β-treated SCID mice. This corresponds to 
typical features of viral glomerulonephritis that displays multinucleated podocytes 
in association with podocyte loss and glomerulosclerosis [40, 230]. This is in line 
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with previous reports on how podocytes enter the cell cycle to undergo 
hypertrophy while the M phase of nuclear division is inhibited by cyclin kinase 
inhibitors at the restriction point during the G2/M phase [13, 221]. This is because 
podocytes are terminally differentiated cells with a complex and sophisticated 
cytoskeletal structure, which links them to neighboring cells via the slit membrane 
[13]. Therefore, stimuli that force podocytes to pass the M-phase of nuclear 
division trigger podocyte death within or shortly after mitosis [13, 231]. This 
variant of cell death was named “mitotic catastrophe” and can involve apoptosis, 
necrosis or both [220, 232].  
 IFN-β and IFN-α aggravates adriamycin nephropathy in SCID mice that 
lack adaptive immunity. This finding implies that the type I IFNs have complex 
immune-regulatory effects on innate and adaptive immunity and distinct direct 
effects on glomerular epithelial cells. Injections of either recombinant IFN-α/β 
both increased the intrarenal expression of ISGs including the chemokine 
CXCL10. CXCL10 attracts proinflammatory macrophages (and cytotoxic T cells) 
via the chemokine receptor CXCR3, explaining the increased numbers of 
intrarenal CD68+ macrophages of SCID mice with both IFNs [233]. This per se 
might be sufficient to explain the associated increase in proteinuria but IFN-β also 
affected the glomerular filtration barrier also via direct effects on podocytes [234]. 
It has been reported that IFN-β ameliorates glomerular injury and proteinuria in 
immunocompetent rodents [200, 201] but this effect was not observed in the 
present study. Balb/c mice injected with adriamycin and treated daily with IFN-α 
and IFN-β showed an aggravated phenotype with increased proteinuria. Balb/c 
mice injected with adriamycin and treated daily with IFN-α and IFN-β showed an 
aggravated phenotype with increased proteinuria. In contrast with what has been 
observed in the SCID mice study, in Balb/c the effect of IFN-α treatment on 
proteinuria was more prominent than observed with IFN-β. Yet, no protection due 
the IFN-β treatment was apparent in the present work. The mild effect on 
proteinuria in Balb/c mice injected with IFN-β might be due to 
immunosuppressive action of IFN-β in an immunocompetent system, together 
with the variability within the group of study. 
 IFN-α and IFN-β had similar effects on proteinuria, glomerular 
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inflammation, and scaring, which should relate to their consistent induction of 
ISGs and chemokines. IFN-α and IFN-β also shared the inhibitory effect on renal 
progenitor differentiation towards podocytes, which favors glomerular scaring 
instead of regeneration[38]. However, IFN-α did not cause immediate changes in 
cell shape that affect the resistance and capacitance of podocyte monolayers and 
did not affect podocyte viability within 24 h. IFN-α was shown to induce cell 
cycle arrest in PECs in-vitro and in-vivo and thus further impair podocyte repair. 
This anti-mitotic effect of IFN-α relates to the induction of p21, a cell cycle 
inhibitor that protects podocytes from cell cycle progression [235, 236].  
 How can IFN-α and IFN-β elicit unique biological effects when they both 
ligate the same IFN-receptor? The IFNAR consists of two transmembranous 
receptor chains with different binding affinities for the sixteen type I IFN variants 
including IFN-α and IFN-β setting off different signaling events which can 
explain their shared and their distinct biological activities [237].  
 What are the clinical implications of these findings? Type I IFNs are 
important mediators of viral infection thus their local effects on podocytes and 
PECs may contribute to podocyte loss, FSGS, and collapsing glomerulopathy, for 
example in viral nephropathies [238, 239]. HIV and parvovirus B19 replicates in 
podocytes and PECs, and viral nucleic acids induce IFN production and ISG 
expression in glomerular cells [175, 176]. Type I IFN also contributes to other 
forms of glomerulonephritis as evidenced by reduced disease activity in IFNAR-
deficient mice [199, 205]. Type I IFNs are also essential mediators of systemic 
lupus and lupus nephritis including local effects on podocytes as shown by the 
IFN-α/β-specific reticular inclusions in podocytes [154, 240]. Finally, 
recombinant types I IFNs are frequently used for the treatment of a number of 
autoimmune diseases and chronic viral hepatitis [225, 241]. The aggravation of 
proteinuria has been reported as a side effect that may relate to the 
pathomechanisms described in this thesis [155, 242].  
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 Figure 26. Schematics of the effects of IFN-α  and IFN-β  on glomerular epithelial cells..  
 
 
 In summary, IFN-α and IFN-β both enhance adriamycin nephropathy in 
SCID mice by intensifying intrarenal inflammation. IFN-β specifically promotes 
podocyte loss by enforcing mitotic catastrophe on podocytes, whereas IFN-α 
affects the proliferation and migration of PECs. Nevertheless, both IFNs impair 
the differentiation of renal progenitors into mature podocytes, which might favor 
focal scaring over glomerular repair. Altogether, these data provide a mechanistic 
model for how the antiviral responses triggered by IFN-α/β drive podocyte loss, 
proteinuria, and glomerulosclerosis (Figure 26). 
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6. Summary 
Even though nucleic acid recognition and IFN-α and IFN-β play an important role 
during viral infections, little is known about their role in viral glomerulonephritis 
e.g. in HIV nephropathy. Viral infections activate systemic antiviral immune 
response, mainly via IFN-α and IFN-β production. These inflammatory cytokines 
have been shown to exert a pleiotropic immunomodulatory effect on renal 
mesangial cells, which directly contribute to glomerular disease. But, it is not 
known whether the viral nucleic acids and type I IFN have an effect on glomerular 
epithelial cells (i.e. podocytes and PECs). Therefore, to investigate the effect of 
nucleic acids on podocytes and PECs, we stimulated these cells with synthetic 
dsDNA (poly-dAdT) complexes with lipofectamine to mimic a viral infection. We 
found that dsDNA consistently induced numerous IFN-stimulated genes in 
podocytes and PECs. Furthermore, we found that dsDNA decreased PECs 
proliferation and inhibited CD24+/CD133+PECs differentiation towards mature 
podocytes. To confirm the hypothesis that this was due to the secretion of IFN-α 
and IFN-β triggered by nucleic acids, we investigated the effect of these antiviral 
cytokines on PECs and podocytes homeostasis. We found that both IFNs 
consistently induced podocytes and PECs to express numerous IFN-stimulated 
genes. However, only IFN-β significantly induced podocyte death and increased 
the permeability of podocyte monolayers. In contrast, only IFN-α caused cell 
cycle arrest by up-regulation of p21 CKD inhibitor and inhibited migration in 
PECs. Both IFNs suppressed CD24+/CD133+PECs differentiation into mature 
podocytes. In adriamycin-induced nephropathy in SCID mice, injections with 
either IFN-α or IFN-β aggravated proteinuria, macrophage influx, and 
glomerulosclerosis. However, only IFN–β induced mitotic podocyte death 
(mitotic catastrophe) leading to reduced podocyte number. We observed that IFN-
α induces cell cycle arrest in PECs in-vivo, which contributes to glomerular 
damage. Balb/c mice injected with adriamycin and treated daily with IFN-α and 
IFN-β showed an aggravated phenotype with increased proteinuria. In contrast to 
what has been observed in the SCID mice study, in Balb/c the effect of IFN-α 
treatment on proteinuria was more prominent compared to IFN-β.  Thus, the type 
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I IFNs have distinct effects on podocytes and parietal epithelial cells, and together 
they promote glomerulosclerosis by enhancing podocyte loss as well as 
suppressing their regeneration from local progenitors. 
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7. Zusammenfassung 
Obwohl die immunstimulatorischen Effekte viraler Nukleinsäursen, wie auch IFN 
-α und IFN-β, während Virusinfektionen eine wichtige Rolle spielen, ist wenig 
über ihre Funktion bei viraler Glomerulonephritis, wie beispielsweise HIV 
Nephropathie, bekannt. Virusinfektionen aktivieren, vor allem mittels IFN-α und 
IFN-β Produktion eine systemische antivirale Immunantwort. Es wurde gezeigt, 
dass diese inflammatorischen Zytokine einen pleiotropen immunmodulatorischen 
Effekt auf renale Mesangialzellen ausüben, was direkt zu glomerulären 
Krankheiten führt. Aber es ist bisher nicht bekannt, ob die viralen Nukleinsäuren 
und Typ I IFN einen Effekt auf die glomerulären Epithelzellen haben. (z.B. 
Podozyten und PECs). Um den Effekt von Nukleinsäuren auf Podozyten und 
PECs zu erforschen, stimulierten wir diese Zellen mit synthetischen dsDNA-
(poly-dAdT) Komplexen mit  lipofectamine, um eine virale Infektion zu imitieren. 
Wir haben herausgefunden, dass dsDNA stetig viele IFN-stimulierte Gene in 
Podozyten und PECs induziert. Desweitern haben wir herausgefunden, dass 
dsDNA  die PECs Proliferation mindert und die CD24+/CD133+PECs 
Differenzierung zu ausgereiften Podozyten inhibiert. Um unsere Hypothese, dass 
deis aufgrund von der Sekretion von IFN-α und IFN-β passiert ist, zu bestätigen, 
haben wir den Effekt von diesen anitviralen Zytokinen auf PECs- und Podozyten-
Homöostase  etabliert. Wir haben herausgefunden, dass beide IFNs stetig 
Podozyten und PECs dazu anregen, stetig mehrere IFN-stimulierte Gene  zu 
exprimieren. Trotzdem hat nur IFN-β das Podozytensterben induziert und die 
Permeabilität der Podozyten-Monolayer erhöht. 
In der Adriamycin-induzierter Nephropathie bei SCID Mäusen haben Injektionen 
mit IFN-α oder IFN-β die Proteinurie, den Makrophagen Influx und die 
Glomerulosklerose verstärkt. Trotzdem induziert nur IFN-β das mitotische  
Podozytensterben (katastrophale Mitose), welches zu einer reduzierten 
Podozytenanzahl führt. Wir haben führt, dass IFN-α einen Zellzyklusarrest in-
vivo bei PECs induziert, der zur glomerulären Schädigung führt. Balb/c Mäuse, 
die Adriamycin gespritzt bekommen haben und täglich mit IFN-α und IFN-
β behandelt wurden zeigten einen aggravierten Phänotyp mit vermehrter 
Proteinurie. Im Gegensatz zu dem, was an Studien in SCID Mausen gezeigt  
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wurde, war der Effekt auf die Proteinurie  nach IFN-α Behandlung prominenter 
bei Balb/c Mäusen, verglichen mit IFN-β. Deshalb haben Typ I IFNs einen 
deutlichen Effekt auf Podozyten und Parietalzellen. Zusammen fördern die Typ I 
IFNs die Glomerulosklerose durch verstärkten Untergang der Podozyten sowie 
durch Unterdrückung ihrer Regeneration aus Vorläuferzellen. 
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9. List of Abbreviations 
AER:    albumin excretion rate 
ACR:    albumin to creatinine ratio 
AIDS:    acquired immunodeficiency syndrome  
AP-1:    activator protein 1 
CKD:    chronic kidney disease  
CLDN1:  claudin 1 
FSGS:   focal segmental glomerulosclerosis  
GBM:    glomerular basement membrane   
GFB:    glomerular filtration barrier  
GFR:    glomerular filtration rate  
HBV:    hepatitis B virus 
HCV:    hepatitis C virus 
HIV:    human immunodeficiency virus (), 
HIVAN:  HIV-associated nephropathy  
IFN:    interferon 
KDIGO:   Kidney Disease Improving Global Outcomes  
NKF-K/DOQI:  National Kidney Foundation Kidney Disease Quality  
   Outcome Initiative  
MPGN:    Membranoproliferative glomerulonephritis  
NPHS1:   nephrin 
NPHS2:   podocin 
NFKB:   nuclear factor kappa-light-chain-enhancer of activated B  
   cells) 
NLRs:   nucleotide-binding oligomerization domains containing  
   (NOD)-like receptors  
NOD:    nucleotide-binding oligomerization domain 
NOS:    not-otherwise -specified variant 
PAMP:   pathogen-associated molecular patterns  
PEC:    parietal epithelial cells  
PRR:    pattern recognition receptors  
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PVB19: parvovirus B19 
RLRs:    retinoic acid-inducible gene (RIG)-I-like receptors   
SCID:   severe combined immunodeficient    
SLE:    Systemic lupus erythematosus  
TIR:   toll-interleukine 1 receptor  
TLRs:   toll-like receptors  
TRIF:   TIR domain containing adapter inducing IFN-β 
TUNEL:  terminal deoxynucleotidyl transferase mediated dUTP Nick 
   End Labeling  
WT-1:   Williams tumor protein-1 
ZO-1:    zonula occludens-1 
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10. Appendix 
Composition of buffers used 
Annexin V/PI Buffer :  
10mM Hepes ;140mM NaCl;2,5CaCl2 
Hepes   2,40 g 
NaCl   8,26g (0.1 % )  
CaCl2  222 mg  
 
Ripa Buffer:  
50 mM Tris-HCl (pH 8);150 mM NaCl, 1% NP-40; 0,05%sodium 
deoxycholate, 0,1% SDS  
For 1000 ml:  
Tris-HCL                         6,057 g  
NaCl                          8,772 g  
NP-40                             10 ml  
Sodium deoxycholate    0,5 ml 
SDS                                          1 ml 
 
10X HBSS (Hank’s Balanced Saline Solution) with Ca, Mg:  
For 1000 ml  
KCl     4 g  
KH
2
PO
4    
0,6 g  
NaCl     80 g  
Na
2
HPO
4
.2H
2
O   0,621 g  
NaHCO
3    
3.5 g  
CaCl
2     
1,4 g (or CaCl
2
.2H
2
O 1,854 g)  
MgCl
2
.6H
2
O   1 g  
MgSO
4
.7H
2
O    1 g  
D-Glucose    10 g  
Dissolve in 900 ml of distilled water and adjust to pH 7.4 with 1N HCl or 
1N NaOH. Make up the volume with distilled water to 1000 ml.  
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10X HBSS (Hank’s Balanced Saline Solution) without Ca, Mg:  
For 1000 ml  
KCl     4 g  
KH2PO4    0,6 g 
NaCl     80 g  
Na
2
HPO
4
.2H
2
O   0,621 g  
Dissolve in 1000 ml and autoclave.  
 
50 % Glycerol in 20 mM Tris-HCl (pH 7.5);1 mM MgCl
2
:  
a. 0,48 g of Tris-HCl in 100 ml of distilled water, adjust pH to 7,4 
(= 40 mM)  
b. 50 ml of Glycerol 100 % + 50 ml of 40 mM Tris-HCl (20 mM)  
c. Add 100 µl of 1M MgCl
2 
solution.  
 
 
EDTA 2 mM: 
EDTA 7,44 mg in 10 ml HBSS (without Ca, Mg) 
To be preheated in 37 °C water bath before use. 
 
MACS Buffer: 
PBS pH 7.2 
0,5% bovine serum albumin 
2 mM EDTA 
 
Citrate buffer 10X: 
110 mM Sodiumcitrate in ddH2O 
with 2N NaOH to pH 6 
 
PBS: 
2,74 M NaCl 
54 mM KCl 
30 mM KH2PO4 
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130 mM Na2HPO4 
in ddH2O 
Adjust pH to 7,5 with HCl 
 
Gel Running Buffer (10x): 
  Tris        30g 
  Glycine    144g 
  SDS          5g 
 Make up volume to 1000ml (pH 8.3) 
 
Transfer Buffer (1x): 
  Tris         1,5g 
  Glycine  7,2g 
 Make up volume to 500ml  
 
TBS (10x): 
  Tris        24,23g 
  NaCl       80,06g 
  Conc. HCL around 17,5ml 
 Make up volume to 1000ml (pH 7,6) 
 
TBS-T (1x): 
  TBS (1x)      1000ml 
  Tween 20     1ml 
 
Sample buffer: 
  Milipore water   3,8 ml 
0,5 M Tris HCl, pH 6,8  1 ml 
Glycerol   0,8 ml 
10% SDS   1,6 ml 
2- mercaptoehanol  0,4 ml 
1% (w/v) bromophenol blue  0,4 ml 
  Total: 8 ml 
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Separating Buffer (1x): 
  Tris (1.5mM)         18,2g 
  SDS             400mg 
 Make up volume to 100ml (pH 8.8) 
 
Stacking Buffer (1x): 
  Tris (0.5mM)       6,05g 
  SDS             400mg 
 Make up volume to 100ml (pH 6.8) 
 
Staining solution: 
  Methanol   500ml 
  Acetic acid    100ml 
  Water    400ml 
 Coomasie Brilliant blue R : 2.5 g  (0.25%) 
 
Destaining solution: 
  Methanol   150ml 
  Acetic acid    100ml 
  Water    750ml 
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